

Cardiometabolic Risk of Second-Generation Antipsychotic Use in Children and Adolescents

JAMA - Journal of the American Medical Association

302, 1765

DOI: [10.1001/jama.2009.1549](https://doi.org/10.1001/jama.2009.1549)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Implications of Marked Weight Gain Associated With Atypical Antipsychotic Medications in Children and Adolescents. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1811.	3.8	40
2	Treatment of Children with Severe Mood Dysregulation. <i>Child and Adolescent Psychopharmacology News</i> , 2009, 14, 7-11.	0.1	1
4	Psychopharmacology News and Views. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2009, 19, 777-778.	0.7	0
5	Adverse Events Associated With Psychotropic Treatment in African American Children and Adolescents. <i>Journal of the National Medical Association</i> , 2010, 102, 375-383.	0.6	10
6	Metabolic syndrome with the atypical antipsychotics. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2010, 17, 460-466.	1.2	149
7	Cardiovascular risk assessment and cholesterol management in adolescents: getting to the heart of the matter. <i>Current Opinion in Pediatrics</i> , 2010, 22, 398-404.	1.0	28
8	Treatment of early-onset schizophrenia. <i>Current Opinion in Psychiatry</i> , 2010, 23, 304-310.	3.1	39
10	Cardiovascular aspects of antipsychotics. <i>Current Opinion in Psychiatry</i> , 2010, 23, 574-581.	3.1	72
13	D-Cycloserine Augmentation of Cognitive-Behavioral Therapy: Directions for Pilot Research in Pediatric Obsessive-Compulsive Disorder. <i>Child and Youth Care Forum</i> , 2010, 39, 101-112.	0.9	14
14	Aripiprazole for the maintenance treatment of bipolar I disorder: A review. <i>Clinical Therapeutics</i> , 2010, 32, S32-S38.	1.1	24
15	Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment. <i>Human Psychopharmacology</i> , 2010, 25, 133-138.	0.7	28
16	The Scandinavian Solutions for Wellness study - a two-arm observational study on the effectiveness of lifestyle intervention on subjective well-being and weight among persons with psychiatric disorders. <i>BMC Psychiatry</i> , 2010, 10, 42.	1.1	24
18	Pediatric bipolar disorder: evidence for prodromal states and early markers. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2010, 51, 459-471.	3.1	75
19	Editorial: Developmental transitions to psychopathology: from genomics and epigenomics to social policy. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2010, 51, 333-340.	3.1	4
20	Mifepristone Reduces Weight Gain and Improves Metabolic Abnormalities Associated With Risperidone Treatment in Normal Men. <i>Obesity</i> , 2010, 18, 2295-2300.	1.5	43
21	Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 545-547.	2.2	23
22	Targeted Care Plans for Schizophrenia. <i>CNS Spectrums</i> , 2010, 15, 6-9.	0.7	0
23	Relationships between the use of second-generation antipsychotics and changes in total cholesterol levels in children and adolescents perinatally infected with HIV. <i>Neurobehavioral HIV Medicine</i> , 2010, 39.	2.0	0

#	ARTICLE	IF	CITATIONS
24	Past and Present Progress in the Pharmacologic Treatment of Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1115-1124.	1.1	188
25	Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients. <i>Neuropsychiatric Disease and Treatment</i> , 2010, 6, 749.	1.0	14
26	Emerging role of aripiprazole for treatment of irritability associated with autistic disorder in children and adolescents. <i>Adolescent Health, Medicine and Therapeutics</i> , 2010, 1, 105.	0.7	7
27	Stimulant-Responsive and Stimulant-Refractory Aggressive Behavior Among Children With ADHD. <i>Pediatrics</i> , 2010, 126, e796-e806.	1.0	84
28	Risks From Antipsychotic Medications in Children and Adolescents. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 729.	3.8	10
29	Use of Metformin to Control Clozapine-Associated Weight Gain in an Adolescent with Schizoaffective Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2010, 20, 153-157.	0.7	6
31	Some Effects of Risperidone and Quetiapine on Growth Parameters and Hormone Levels in Young Pigtail Macaques. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2010, 20, 489-493.	0.7	13
32	Six Months of Treatment with Risperidone May Be Associated with Nonsignificant Abnormalities of Liver Function Tests in Children and Adolescents: A Longitudinal, Observational Study from Turkey. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2010, 20, 407-413.	0.7	11
33	Adolescent with Treatment-Refractory Schizophrenia and Clozapine-Induced Cardiomyopathy Managed with High-Dose Olanzapine. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2010, 20, 539-543.	0.7	12
34	Age-Dependent Metabolic Effects of Second-Generation Antipsychotics in Second-Generation Antipsychotic-Naïve French Canadian Patients. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2010, 20, 479-487.	0.7	15
35	Effectiveness and Tolerability of Aripiprazole in Children and Adolescents with Tourette's Disorder: A Pilot Study in China. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2010, 20, 291-298.	0.7	45
36	Modifying the risk of atypical antipsychotics in the treatment of juvenile-onset schizophrenia. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 195-205.	0.9	3
37	Hyperprolactinemia with Antipsychotic Drugs in Children and Adolescents. <i>International Journal of Pediatric Endocrinology (Springer)</i> , 2010, 2010, 1-6.	1.6	19
38	World Congress on the Insulin Resistance Syndrome, 2009. <i>Diabetes Care</i> , 2010, 33, e124-e130.	4.3	0
39	Utility of Childhood Glucose Homeostasis Variables in Predicting Adult Diabetes and Related Cardiometabolic Risk Factors: The Bogalusa Heart Study: Comment on Nguyen et al.. <i>Diabetes Care</i> , 2010, 33, e123-e123.	4.3	1
40	Metabolic Screening in Children Receiving Antipsychotic Drug Treatment. <i>JAMA Pediatrics</i> , 2010, 164, 344-51.	3.6	136
41	National Trends in Child and Adolescent Psychotropic Polypharmacy in Office-Based Practice, 1996-2007. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2010, 49, 1001-1010.	0.3	228
43	Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients. <i>Neuropsychopharmacology</i> , 2010, 35, 1997-2004.	2.8	183

#	ARTICLE	IF	CITATIONS
45	Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: A randomized five month study. <i>Schizophrenia Research</i> , 2010, 120, 204-209.	1.1	30
46	Differential characteristics of the efficacy and tolerability of second-generation antipsychotics in the treatment of psychotic disorders in children and adolescents. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2010, 3, 152-167.	0.2	1
47	Sleep Problems in the Child with Attention-Deficit Hyperactivity Disorder. <i>CNS Drugs</i> , 2010, 24, 811-828.	2.7	73
48	Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2557-2567.	0.9	13
49	Abuse-Deterrent and Tamper-Resistant Opioid Formulations. <i>CNS Drugs</i> , 2010, 24, 805-810.	2.7	49
50	The role of comorbid disruptive behavior in the clinical expression of pediatric obsessive-compulsive disorder. <i>Behaviour Research and Therapy</i> , 2010, 48, 1204-1210.	1.6	59
51	Complications of Antipsychotic Therapy in Children With Tourette Syndrome. <i>Pediatric Neurology</i> , 2010, 43, 17-20.	1.0	21
52	Antipsychotic drug side effects for persons with intellectual disability. <i>Research in Developmental Disabilities</i> , 2010, 31, 1570-1576.	1.2	105
53	Antipsychotic medication, mortality and neurodegeneration: The need for more selective use and lower doses. <i>Psychosis</i> , 2010, 2, 50-69.	0.4	16
54	Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. <i>Schizophrenia Research</i> , 2010, 117, 68-74.	1.1	99
55	Childhood obesity. <i>Lancet, The</i> , 2010, 375, 1737-1748.	6.3	1,203
56	Swedish clinical guidelines��Prevention and management of metabolic risk in patients with severe psychiatric disorders. <i>Nordic Journal of Psychiatry</i> , 2010, 64, 294-302.	0.7	39
57	Commentary: The Public Health Consequences of an Industry-Influenced Psychiatric Taxonomy: ��Attenuated Psychotic Symptoms Syndrome��as a Case Example. <i>Accountability in Research</i> , 2010, 17, 264-269.	1.6	3
58	Long-term effectiveness of aripiprazole in adolescents and young adults with bipolar disorder: A naturalistic study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2010, 14, 252-256.	1.2	5
59	Efficacy of Metformin and Topiramate in Prevention and Treatment of Second-Generation Antipsychotic��Induced Weight Gain. <i>Annals of Pharmacotherapy</i> , 2010, 44, 668-679.	0.9	38
60	Management of antipsychotic-related weight gain. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 1175-1200.	1.4	95
61	Important to identify and treat sleep problems in children with attention-deficit hyperactivity disorder (ADHD). <i>Drugs and Therapy Perspectives</i> , 2011, 27, 15-17.	0.3	0
62	An Open-Label Trial of Risperidone in Children and Adolescents with Severe Mood Dysregulation. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 237-243.	0.7	48

#	ARTICLE	IF	CITATIONS
63	Antipsychotic Drug Administration Does Not Correlate with Prolonged Rate-Corrected QT Interval in Children and Adolescents: Results from a Nested Case-€“Control Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 365-368.	0.7	28
64	Chronic Disease Risks in Young Adults With Autism Spectrum Disorder: Forewarned Is Forearmed. <i>American Journal on Intellectual and Developmental Disabilities</i> , 2011, 116, 371-380.	0.8	121
65	Long-Term Aripiprazole in Youth With Developmental Disabilities Including Autism. <i>Journal of Mental Health Research in Intellectual Disabilities</i> , 2011, 4, 40-52.	1.3	12
66	Antipsychotic drug toxicology in children. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 591-608.	1.5	28
68	Prevention of Metabolic Syndrome in Serious Mental Illness. <i>Psychiatric Clinics of North America</i> , 2011, 34, 109-125.	0.7	17
69	Atypical Antipsychotic-Induced Weight Gain. <i>CNS Drugs</i> , 2011, 25, 1035-1059.	2.7	142
70	Weight Gain and Metabolic Risks Associated with Antipsychotic Medications in Children and Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 517-535.	0.7	221
71	Psychopharmacology of Schizophrenia in Children and Adolescents. <i>Pediatric Clinics of North America</i> , 2011, 58, 205-218.	0.9	11
72	Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism. <i>Physiology and Behavior</i> , 2011, 104, 590-598.	1.0	51
73	Management of Schizophrenia in Children and Adolescents. <i>Drugs</i> , 2011, 71, 179-208.	4.9	78
74	Metabolic and Neurological Complications of Second-Generation Antipsychotic Use in Children. <i>Drug Safety</i> , 2011, 34, 651-668.	1.4	117
75	Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. <i>World Psychiatry</i> , 2011, 10, 138-151.	4.8	631
76	Weight Gain and Metabolic Syndrome Among Young Patients on Antipsychotic Medication: What do we Know and Where do we go?. <i>Australasian Psychiatry</i> , 2011, 19, 232-235.	0.4	27
77	Antipsychotic drugs and obesity. <i>Trends in Molecular Medicine</i> , 2011, 17, 97-107.	3.5	256
78	Controversies Surrounding Pediatric Psychopharmacology. <i>Advances in Pediatrics</i> , 2011, 58, 153-179.	0.5	7
79	A real-world data analysis of dose effect of second-generation antipsychotic therapy on hemoglobin A1C level. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1326-1332.	2.5	14
80	Effectiveness and safety of antipsychotics in early onset psychoses: A long-term comparison. <i>Psychiatry Research</i> , 2011, 189, 349-356.	1.7	18
81	Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. <i>European Psychiatry</i> , 2011, 26, 144-158.	0.1	302

#	ARTICLE	IF	CITATIONS
82	Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons. <i>European Neuropsychopharmacology</i> , 2011, 21, 621-645.	0.3	168
83	Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: A review of the randomized controlled studies. <i>European Neuropsychopharmacology</i> , 2011, 21, 600-620.	0.3	108
84	The Impact of Cardiometabolic Risk in Patients with Severe Mental Illness: From Evidence to Clinical Management. , 0, , .		0
85	Association of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study). <i>Frontiers in Genetics</i> , 2011, 2, 56.	1.1	19
86	Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. <i>Paediatrics and Child Health</i> , 2011, 16, 581-589.	0.3	116
87	The Effect of Long-Term Use of Risperidone on Body Weight of Children With an Autism Spectrum Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 669-670.	0.7	11
88	Health Monitoring and Promotion Among Youths With Psychiatric Disorders: Program Development and Initial Findings. <i>Psychiatric Services</i> , 2011, 62, 1331-1337.	1.1	4
89	Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents. <i>Yearbook of Pediatrics</i> , 2011, 2011, 423-425.	0.2	0
90	Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder. <i>Yearbook of Pediatrics</i> , 2011, 2011, 78-80.	0.2	0
91	Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents. <i>Yearbook of Psychiatry and Applied Mental Health</i> , 2011, 2011, 319-321.	0.1	0
92	Management recommendations for metabolic complications associated with second-generation antipsychotic use in children and youth. <i>Paediatrics and Child Health</i> , 2011, , .	0.3	16
94	Fatty acids and schizophrenia. , 2011, , 464-483.		0
95	Weight gain associated with taking psychotropic medication: An integrative review. <i>International Journal of Mental Health Nursing</i> , 2011, 20, 202-222.	2.1	84
96	Antipsychotic prescribing: old wine in new bottles?. <i>Child and Adolescent Mental Health</i> , 2011, 16, 218-221.	1.8	2
97	Metabolic abnormalities in an early psychosis service: a retrospective, naturalistic cross-sectional study. <i>Microbial Biotechnology</i> , 2011, 5, 108-114.	0.9	52
98	Influence of resting energy expenditure on weight gain in adolescents taking second-generation antipsychotics. <i>Clinical Nutrition</i> , 2011, 30, 616-623.	2.3	32
99	Selective glucocorticoid receptor (type II) antagonists prevent weight gain caused by olanzapine in rats. <i>European Journal of Pharmacology</i> , 2011, 655, 117-120.	1.7	7
100	Case Series of Behavioral Psychotherapy for Obsessive-Compulsive Symptoms in Youth with Prader-Willi Syndrome. <i>Journal of Developmental and Physical Disabilities</i> , 2011, 23, 359-368.	1.0	3

#	ARTICLE	IF	CITATIONS
101	Obesity and coronary risk in patients treated with second-generation antipsychotics. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011, 261, 417-423.	1.8	29
102	Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents. <i>European Child and Adolescent Psychiatry</i> , 2011, 20, 597-598.	2.8	2
103	Update: Schizophrenia Across Cultures. <i>Current Psychiatry Reports</i> , 2011, 13, 305-311.	2.1	43
104	Pharmacotherapeutic intervention in impulsive preschool children: The need for a comprehensive therapeutic approach. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2011, 5, 11.	1.2	5
105	Childhood Obesity and Environmental Chemicals. <i>Mount Sinai Journal of Medicine</i> , 2011, 78, 22-48.	1.9	143
106	Treatment-resistant depression in adolescents: review and updates on clinical management. <i>Depression and Anxiety</i> , 2011, 28, 946-954.	2.0	68
107	Disruptive Mood Dysregulation Disorder: Clarity or Confusion?. <i>The ADHD Report</i> , 2011, 19, 7-11.	0.4	1
108	Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. <i>World Psychiatry</i> , 2011, 10, 52-77.	4.8	1,767
109	Antipsychotic Medication Use Among Children and Risk of Diabetes Mellitus. <i>Pediatrics</i> , 2011, 128, 1135-1141.	1.0	63
110	Severe Mood Dysregulation, Irritability, and the Diagnostic Boundaries of Bipolar Disorder in Youths. <i>American Journal of Psychiatry</i> , 2011, 168, 129-142.	4.0	473
111	Review on the current use of antipsychotic drugs in children and adolescents. <i>Archives of Disease in Childhood: Education and Practice Edition</i> , 2011, 96, 192-196.	0.3	29
112	Observations in Psychotropic Medication Usage in Patients With Behavior Disorders Presenting to a Specialty Clinic. <i>Clinical Pediatrics</i> , 2011, 50, 44-49.	0.4	1
113	Antipsychotic Treatment Among Youth in Foster Care. <i>Pediatrics</i> , 2011, 128, e1459-e1466.	1.0	89
114	Targeted Intervention to Improve Monitoring of Antipsychotic-Induced Weight Gain and Metabolic Disturbance in First Episode Psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2011, 45, 740-748.	1.3	28
115	Age-Grouped Differences in Adverse Drug Events from Psychotropic Medication. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 299-309.	0.7	33
116	Predictors of Risperidone and 9-Hydroxyrisperidone Serum Concentration in Children and Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 163-169.	0.7	30
117	The Pharmacoepidemiology of Antipsychotic Medications for Canadian Children and Adolescents: 2005-2009. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 537-543.	0.7	79
118	Early Diagnoses and Psychotherapeutic Medication Treatment Experiences of a Cohort of Children Under 6 Years Old Who Received Antipsychotic Treatment in Florida's Medicaid Program. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 79-84.	0.7	17

#	ARTICLE	IF	CITATIONS
119	Liver function tests in children and adolescents receiving risperidone treatment for a year: A longitudinal, observational study from Turkey^a. International Journal of Psychiatry in Clinical Practice, 2011, 15, 204-208.	1.2	9
120	A potential role for adjunctive vitamin D therapy in the management of weight gain and metabolic side effects of second-generation antipsychotics. Journal of Pediatric Endocrinology and Metabolism, 2011, 24, 619-26.	0.4	7
121	Review: metformin is effective at attenuating the metabolic risks associated with use of atypical antipsychotics. Evidence-Based Mental Health, 2011, 14, 55-55.	2.2	4
122	Psychopharmacology in Adolescents. , 2011, , 244-253.		0
123	Drugs for kids: Good or bad?. Journal of Psychiatry and Neuroscience, 2012, 37, 293-295.	1.4	1
124	Psychosocial Treatment to Improve Resilience and Reduce Impairment in Youth With Tics: An Intervention Case Series of Eight Youth. Journal of Cognitive Psychotherapy, 2012, 26, 57-70.	0.2	31
125	A Randomized Controlled Trial of Risperidone, Lithium, or Divalproex Sodium for Initial Treatment of Bipolar I Disorder, Manic or Mixed Phase, in Children and Adolescents. Archives of General Psychiatry, 2012, 69, 515.	13.8	201
126	Adverse Effects of Second-Generation Antipsychotics in Children and Adolescents. Journal of Clinical Psychopharmacology, 2012, 32, 309-316.	0.7	167
127	Trajectories of Agouti-Related Protein and Leptin Levels During Antipsychotic-Associated Weight Gain in Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2012, 32, 767-772.	0.7	16
128	Weight gain and metabolic side effects with antipsychotic drugs in children. Middle East Current Psychiatry, 2012, 19, 237-244.	0.5	0
129	Advances in the treatment of pediatric obsessive-compulsive disorder: rationale and design for the evaluation ofD-cycloserine with exposure and response prevention. Neuropsychiatry, 2012, 2, 291-300.	0.4	13
130	Efficacy and Safety of Quetiapine in Adolescents with Schizophrenia Investigated in a 6-Week, Double-Blind, Placebo-Controlled Trial. Journal of Child and Adolescent Psychopharmacology, 2012, 22, 327-342.	0.7	57
131	Differences in Body Mass Index <i>z</i>-Scores and Weight Status in a Dutch Pediatric Psychiatric Population With and Without Use of Second-Generation Antipsychotics. Journal of Child and Adolescent Psychopharmacology, 2012, 22, 166-173.	0.7	18
132	Comparative Effectiveness of Second-Generation Antipsychotic Medications in Early-Onset Schizophrenia. Schizophrenia Bulletin, 2012, 38, 845-853.	2.3	20
133	An update on lipid profile screening in second-generation antipsychotic users in the USA. Clinical Lipidology, 2012, 7, 509-523.	0.4	1
134	Feasibility of a Nutritional Supplement as Treatment for Pediatric Bipolar Spectrum Disorders. Journal of Alternative and Complementary Medicine, 2012, 18, 678-685.	2.1	27
135	Comparison of Long-Term (At Least 24 Weeks) Weight Gain and Metabolic Changes Between Adolescents and Adults Treated with Olanzapine. Journal of Child and Adolescent Psychopharmacology, 2012, 22, 157-165.	0.7	43
136	Deterioration of metabolic parameters during short-term psychiatric inpatient treatment: A prospective naturalistic study. International Journal of Psychiatry in Clinical Practice, 2012, 16, 8-17.	1.2	1

#	ARTICLE	IF	CITATIONS
137	Psychiatric comorbidity of childhood obesity. <i>International Review of Psychiatry</i> , 2012, 24, 241-246.	1.4	84
138	Metabolic Consequences of Antipsychotic Therapy: Preclinical and Clinical Perspectives on Diabetes, Diabetic Ketoacidosis, and Obesity. <i>Handbook of Experimental Pharmacology</i> , 2012, , 135-164.	0.9	21
139	Do We Really Know How to Treat a Child with Bipolar Disorder or One with Severe Mood Dysregulation? Is There a Magic Bullet?. <i>Depression Research and Treatment</i> , 2012, 2012, 1-9.	0.7	10
140	The psychopharmacology algorithm project at the harvard south shore program: 2012 update on psychotic depression. <i>Journal of Mood Disorders</i> , 2012, 2, 168.	0.1	2
141	Ethical Implications for Clinical Practice and Future Research in "At Risk" Individuals. <i>Current Pharmaceutical Design</i> , 2012, 18, 606-612.	0.9	10
142	Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers. <i>Current Psychiatry Reviews</i> , 2012, 8, 25-36.	0.9	63
143	Metabolic Monitoring Training Program Implementation in the Community Setting Was Associated with Improved Monitoring in Second-Generation Antipsychotic-Treated Children. <i>Canadian Journal of Psychiatry</i> , 2012, 57, 292-299.	0.9	24
144	Are Antipsychotics Effective for the Treatment of Anorexia Nervosa?. <i>Journal of Clinical Psychiatry</i> , 2012, 73, e757-e766.	1.1	91
145	Waist Circumference is a Sensitive Screening Tool for Assessment of Metabolic Syndrome Risk in Children Treated with Second-Generation Antipsychotics. <i>Canadian Journal of Psychiatry</i> , 2012, 57, 34-44.	0.9	47
146	Gap between recommended and actual practice in pediatric obsessive-compulsive disorder. <i>Clinical Practice (London, England)</i> , 2012, 9, 153-159.	0.1	0
147	Ten Years of Antipsychotic Prescribing to Children: A Canadian Population-Based Study. <i>Canadian Journal of Psychiatry</i> , 2012, 57, 52-58.	0.9	89
148	Second-Generation Antipsychotics for the Treatment of Disruptive Behaviour Disorders in Children: A Systematic Review. <i>Canadian Journal of Psychiatry</i> , 2012, 57, 722-727.	0.9	36
149	The Relationship between Mental Health Diagnosis and Treatment with Second-Generation Antipsychotics over Time: A National Study of U.S. Medicaid-Enrolled Children. <i>Health Services Research</i> , 2012, 47, 1836-1860.	1.0	78
150	Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. <i>Nature Reviews Endocrinology</i> , 2012, 8, 114-126.	4.3	832
151	Antipsychotics for Children and Young Adults: A Comparative Effectiveness Review. <i>Pediatrics</i> , 2012, 129, e771-e784.	1.0	97
152	The Role of Co-Occurring Disruptive Behavior in the Clinical Presentation of Children and Adolescents with Anxiety in the Context of Autism Spectrum Disorders. <i>Child Psychiatry and Human Development</i> , 2012, 43, 734-746.	1.1	32
153	A fuzzy cognitive map of the psychosocial determinants of obesity. <i>Applied Soft Computing Journal</i> , 2012, 12, 3711-3724.	4.1	80
154	Rate of Weight Gain and Cardiometabolic Abnormalities in Children and Adolescents. <i>Journal of Pediatrics</i> , 2012, 161, 1010-1015.e1.	0.9	21

#	ARTICLE	IF	CITATIONS
155	Atypical antipsychotics for disruptive behaviour disorders in children and youths. , 2012, , CD008559.		47
156	Adverse Effects and Toxicity of the Atypical Antipsychotics: What Is Important for the Pediatric Emergency Medicine Practitioner?. Clinical Pediatric Emergency Medicine, 2012, 13, 300-310.	0.4	28
157	Efectos secundarios del tratamiento antipsicótico en niños y adolescentes naïve o quasi-naïve: diseño de un protocolo de seguimiento y resultados basales. Revista De Psiquiatría Y Salud Mental, 2012, 5, 217-228.	1.0	15
158	Empirical Evidence for Psychopharmacologic Treatment in Early-Onset Psychosis and Schizophrenia. Child and Adolescent Psychiatric Clinics of North America, 2012, 21, 885-909.	1.0	8
159	Pharmacologic Treatment of Bipolar Disorder in Children and Adolescents. Child and Adolescent Psychiatric Clinics of North America, 2012, 21, 911-939.	1.0	39
160	Child and Adolescent Depression Intervention Overview: What Works, for Whom and How Well?. Child and Adolescent Psychiatric Clinics of North America, 2012, 21, 299-312.	1.0	45
161	Management of Psychotropic Medication Side Effects in Children and Adolescents. Child and Adolescent Psychiatric Clinics of North America, 2012, 21, 713-738.	1.0	11
162	Outpatient treatment of children and adolescents with antipsychotic drugs in Croatia. Nordic Journal of Psychiatry, 2012, 66, 2-7.	0.7	8
163	Effects of sports participation on psychiatric symptoms and brain activations during sports observation in schizophrenia. Translational Psychiatry, 2012, 2, e96-e96.	2.4	41
164	Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 36, 213-219.	2.5	3
165	Association Between Common Variants Near the Melanocortin 4 Receptor Gene and Severe Antipsychotic Drug-Induced Weight Gain. Archives of General Psychiatry, 2012, 69, 904.	13.8	165
166	Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain. Bone, 2012, 50, 490-498.	1.4	37
167	Body composition in patients with schizophrenia: Comparison with healthy controls. Annals of General Psychiatry, 2012, 11, 11.	1.2	23
168	Body Weight and Metabolic Adverse Effects of Asenapine, Iloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder. CNS Drugs, 2012, 26, 733-759.	2.7	136
169	Pharmacogenetics in psychiatry: translating research into clinical practice. Molecular Psychiatry, 2012, 17, 760-769.	4.1	76
170	Safety and tolerability of antipsychotic polypharmacy. Expert Opinion on Drug Safety, 2012, 11, 527-542.	1.0	163
171	Omega-3 fatty acid deficiency augments risperidone-induced hepatic steatosis in rats: Positive association with stearoyl-CoA desaturase. Pharmacological Research, 2012, 66, 283-291.	3.1	10
172	Secondary effects of antipsychotic treatment in naïve or quasi-naïve children and adolescents: Design of a follow-up protocol and baseline results. Revista De Psiquiatría Y Salud Mental (English Edition), 2012, 5, 217-228.	0.2	8

#	ARTICLE	IF	CITATIONS
173	Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trials. <i>Schizophrenia Research</i> , 2012, 140, 159-168.	1.1	161
174	Advances in Pediatric Pharmacology, Therapeutics, and Toxicology. <i>Advances in Pediatrics</i> , 2012, 59, 27-45.	0.5	2
175	Interventions for Youth at High Risk for Bipolar Disorder and Schizophrenia. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2012, 21, 739-751.	1.0	12
176	Cardiometabolic risk and the MTHFR C677T variant in children treated with second-generation antipsychotics. <i>Translational Psychiatry</i> , 2012, 2, e71-e71.	2.4	28
177	Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 1143-1161.	1.4	92
178	Correlates of weight gain during long-term risperidone treatment in children and adolescents. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2012, 6, 21.	1.2	12
179	Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs. <i>Frontiers in Psychiatry</i> , 2012, 3, 62.	1.3	25
180	Des recommandations probantes pour surveiller l'innocuité des antipsychotiques de deuxième génération chez les enfants et les adolescents. <i>Paediatrics and Child Health</i> , 2012, 17, 12B-21B.	0.3	1
181	Les recommandations de prise en charge des complications métaboliques associées aux antipsychotiques de deuxième génération chez les enfants et les adolescents. <i>Paediatrics and Child Health</i> , 2012, 17, 5B-11B.	0.3	0
182	Zonisamide for Attenuation of Weight Gain in a Morbidly-Obese Adolescent on an Antipsychotic. <i>Journal of Obesity & Weight Loss Therapy</i> , 2012, 02, .	0.1	1
183	The cardiovascular health of young people with severe mental illness: addressing an epidemic within an epidemic. <i>The Psychiatrist</i> , 2012, 36, 375-378.	0.3	21
184	Epidemiologic and Clinical Perspectives on Antipsychotic Treatment of Children and Adolescents. <i>Canadian Journal of Psychiatry</i> , 2012, 57, 715-716.	0.9	6
185	Treatment of Maladaptive Aggression in Youth: CERT Guidelines II. Treatments and Ongoing Management. <i>Pediatrics</i> , 2012, 129, e1577-e1586.	1.0	117
186	Psychotropic Medications in Autism: Practical Considerations for Parents. <i>Journal of Autism and Developmental Disorders</i> , 2012, 42, 1249-1255.	1.7	17
187	Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters. <i>Psychopharmacology</i> , 2012, 221, 155-169.	1.5	231
188	Efficacy and safety of aripiprazole in child and adolescent patients. <i>European Child and Adolescent Psychiatry</i> , 2012, 21, 361-368.	2.8	41
189	Interstate variation in trends of psychotropic medication use among Medicaid-enrolled children in foster care. <i>Children and Youth Services Review</i> , 2012, 34, 1492-1499.	1.0	65
190	Antipsychotics in pediatric and adolescent patients: A review of comparative safety data. <i>Journal of Affective Disorders</i> , 2012, 138, S22-S30.	2.0	73

#	ARTICLE	IF	CITATIONS
191	Aripiprazole in pediatric psychosis and bipolar disorder: A clinical review. <i>Journal of Affective Disorders</i> , 2012, 138, S15-S21.	2.0	16
192	The heart of the matter: cardiometabolic care in youth with psychosis. <i>Microbial Biotechnology</i> , 2012, 6, 347-353.	0.9	82
193	Attention to body mass index by child psychiatry providers when prescribing second-generation antipsychotic medication to children: a survey study using a clinical vignette. <i>Microbial Biotechnology</i> , 2012, 6, 195-200.	0.9	0
194	Managing the Metabolic Side Effects of Atypical Antipsychotics. <i>Journal of Child and Adolescent Psychiatric Nursing</i> , 2012, 25, 54-55.	0.8	2
195	Utilisation des antipsychotiques chez l'enfant et l'adolescent. <i>Neuropsychiatrie De L'Enfance Et De L'Adolescence</i> , 2012, 60, 12-19.	0.1	16
196	Physical health and wellbeing of emerging and young adults with mental illness: An integrative review of international literature. <i>International Journal of Mental Health Nursing</i> , 2012, 21, 274-288.	2.1	71
197	Design and Subject Characteristics in the Federally-Funded Citalopram Trial in Children with Pervasive Developmental Disorders. <i>Journal of Autism and Developmental Disorders</i> , 2012, 42, 432-440.	1.7	8
198	Role of long-chain omega-3 fatty acids in psychiatric practice. <i>PharmaNutrition</i> , 2013, 1, 41-49.	0.8	42
199	Adiposity and Insulin Resistance in Humans: The Role of the Different Tissue and Cellular Lipid Depots. <i>Endocrine Reviews</i> , 2013, 34, 463-500.	8.9	204
200	A Retrospective Study of Amitriptyline in Youth with Autism Spectrum Disorders. <i>Journal of Autism and Developmental Disorders</i> , 2013, 43, 1017-1027.	1.7	13
201	Clinician uptake of obesity-related drug information: a qualitative assessment using continuing medical education activities. <i>Nutrition Journal</i> , 2013, 12, 44.	1.5	3
202	Pharmacoepidemiology of Antipsychotic Use in Youth with ADHD: Trends and Clinical Implications. <i>Current Psychiatry Reports</i> , 2013, 15, 382.	2.1	35
203	Add-on fluvoxamine treatment for schizophrenia: an updated meta-analysis of randomized controlled trials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 633-641.	1.8	15
204	Antipsychotics and the Risk of Type 2 Diabetes Mellitus in Children and Youth. <i>JAMA Psychiatry</i> , 2013, 70, 1067.	6.0	194
205	Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review. <i>European Child and Adolescent Psychiatry</i> , 2013, 22, 457-479.	2.8	60
207	Association Between Second-Generation Antipsychotics and Changes in Body Mass Index in Adolescents. <i>Journal of Adolescent Health</i> , 2013, 52, 336-343.	1.2	13
209	Treatment decisions for chronic tic disorders. <i>Clinical Practice (London, England)</i> , 2013, 10, 765-780.	0.1	4
210	Gynecologic and Reproductive Health Concerns of Adolescents Using Selected Psychotropic Medications. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2013, 26, 7-15.	0.3	9

#	ARTICLE	IF	CITATIONS
211	Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat. <i>Translational Psychiatry</i> , 2013, 3, e309-e309.	2.4	201
212	Practice Parameter for the Assessment and Treatment of Children and Adolescents With Schizophrenia. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2013, 52, 976-990.	0.3	213
213	Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2013, 7, 31.	1.2	19
214	Efficacy and Tolerability of Perospirone in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>CNS Drugs</i> , 2013, 27, 731-741.	2.7	15
215	Psychotropic drug prescribing in an Australian specialist child and adolescent eating disorder service: a retrospective study. <i>Journal of Eating Disorders</i> , 2013, 1, 27.	1.3	9
216	Antipsychotic-Induced Dyslipidemia Treated with Omega 3 Fatty Acid Supplement in an 11-Year-Old Psychotic Child: A 1-Year Follow-up. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 139-141.	0.7	11
217	Antipsychotic-Induced Insulin Resistance and Postprandial Hormonal Dysregulation Independent of Weight Gain or Psychiatric Disease. <i>Diabetes</i> , 2013, 62, 3232-3240.	0.3	152
218	Adult rats treated with risperidone during development are hyperactive.. <i>Experimental and Clinical Psychopharmacology</i> , 2013, 21, 259-267.	1.3	20
219	Current Trends in the Pharmacological Treatment of Autism Spectrum Disorders. , 2013, , 85-101.		0
220	Assessing Cognitive Therapy Instead Of Neuroleptics: Rationale, study design and sample characteristics of the ACTION trial. <i>Psychosis</i> , 2013, 5, 82-92.	0.4	10
221	Efficacy of risperidone in children with disruptive behavioural disorders. <i>Journal of Paediatrics and Child Health</i> , 2013, 49, 19-26.	0.4	5
222	Psychopharmacologic Treatment of Psychosis in Children and Adolescents. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2013, 22, 727-744.	1.0	21
223	Early Antipsychotic Response to Aripiprazole in Adolescents With Schizophrenia: Predictive Value for Clinical Outcomes. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2013, 52, 689-698.e3.	0.3	23
224	Efficacy and safety of NMDA receptor antagonists augmentation therapy for schizophrenia: An updated meta-analysis of randomized placebo-controlled trials. <i>Journal of Psychiatric Research</i> , 2013, 47, 2018-2020.	1.5	20
225	Psychotropic medication use in youth at high risk for psychosis: Comparison of baseline data from two research cohorts 1998â€“2005 and 2008â€“2011. <i>Schizophrenia Research</i> , 2013, 148, 99-104.	1.1	33
226	NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials. <i>Journal of Psychiatric Research</i> , 2013, 47, 1143-1149.	1.5	49
228	Efficacy and safety of noradrenalin reuptake inhibitor augmentation therapy for schizophrenia: A meta-analysis of double-blind randomized placebo-controlled trials. <i>Journal of Psychiatric Research</i> , 2013, 47, 1557-1563.	1.5	10
229	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. <i>Bipolar Disorders</i> , 2013, 15, 1-44.	1.1	740

#	ARTICLE	IF	CITATIONS
230	Basic treatment principles for psychotic disorders in patients with epilepsy. <i>Epilepsia</i> , 2013, 54, 19-33.	2.6	42
231	Iron Deficiency in Pediatric Patients in Long-Term Risperidone Treatment. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 101-109.	0.7	15
232	Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. <i>Bipolar Disorders</i> , 2013, 15, 138-149.	1.1	62
233	Psychotropic Medication Treatment of Adolescents: Results From the National Comorbidity Survey-Adolescent Supplement. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2013, 52, 378-388.	0.3	45
234	Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 61-91.	1.3	22
235	Nutritional and Safety Outcomes from an Open-Label Micronutrient Intervention for Pediatric Bipolar Spectrum Disorders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 558-567.	0.7	19
236	Early Intervention for Symptomatic Youth at Risk for Bipolar Disorder: A Randomized Trial of Family-Focused Therapy. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2013, 52, 121-131.	0.3	186
237	Risperidone or aripiprazole in children and adolescents with autism and/or intellectual disability: A Bayesian meta-analysis of efficacy and secondary effects. <i>Research in Autism Spectrum Disorders</i> , 2013, 7, 167-175.	0.8	43
238	Psychosocial Treatment Efficacy for Disruptive Behavior Problems in Very Young Children: A Meta-Analytic Examination. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2013, 52, 26-36.	0.3	216
239	Associations Among Obesity, Acute Weight Gain, and Response to Treatment with Olanzapine in Adolescent Schizophrenia. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 522-530.	0.7	35
240	Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. <i>Molecular Psychiatry</i> , 2013, 18, 53-66.	4.1	136
241	Antipsychotic Use by Medicaid-Insured Youths: Impact of Eligibility and Psychiatric Diagnosis Across a Decade. <i>Psychiatric Services</i> , 2013, 64, 223-229.	1.1	65
242	Metformin for Weight Loss and Metabolic Control in Overweight Outpatients With Schizophrenia and Schizoaffective Disorder. <i>American Journal of Psychiatry</i> , 2013, 170, 1032-1040.	4.0	118
243	Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 987-995.	1.0	69
244	Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1205-1218.	1.0	257
245	Possible mechanisms for the skeletal effects of antipsychotics in children and adolescents. <i>Therapeutic Advances in Psychopharmacology</i> , 2013, 3, 278-293.	1.2	33
246	Attention-deficit/hyperactivity disorder: are we helping or harming?. <i>BMJ</i> , The, 2013, 347, f6172-f6172.	3.0	91
247	Review: limited evidence that risperidone reduces aggression and conduct problems in the short term in children and adolescents with disruptive behaviour disorders. <i>Evidence-Based Mental Health</i> , 2013, 16, 69-69.	2.2	2

#	ARTICLE	IF	CITATIONS
248	Tolerability and safety profile of risperidone in a sample of children and adolescents. <i>International Clinical Psychopharmacology</i> , 2013, 28, 1.	0.9	24
249	CNR1 Gene and Risk of the Metabolic Syndrome in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 186-192.	0.7	30
250	Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro. <i>Journal of Lipid Research</i> , 2013, 54, 310-324.	2.0	87
251	Twenty-Four Months of Antipsychotic Treatment in Children and Adolescents With First Psychotic Episode. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 463-471.	0.7	23
252	Treatment of adolescents with early-onset schizophrenia spectrum disorders. <i>Current Opinion in Psychiatry</i> , 2013, 26, 219-230.	3.1	82
253	Weight gain induced by psychotropic agents. <i>Cmaj</i> , 2013, 185, 898-898.	0.9	0
254	The developmental psychopathology of irritability. <i>Development and Psychopathology</i> , 2013, 25, 1473-1487.	1.4	195
255	Bridging the gap from evidence to policy and practice: Reducing the progression to metabolic syndrome for children and adolescents on antipsychotic medication. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 435-442.	1.3	16
256	CriticalThinkRx May Reduce Psychiatric Prescribing to Foster Youth. <i>Research on Social Work Practice</i> , 2013, 23, 284-293.	1.1	9
257	The Psychopharmacology Algorithm Project at the Harvard South Shore Program. <i>Harvard Review of Psychiatry</i> , 2013, 21, 18-40.	0.9	38
258	Long-Chain Omega-3 Fatty Acids in Child and Adolescent Psychiatry: I. Phenomenology. <i>Child and Adolescent Psychopharmacology News</i> , 2013, 18, 1-7,14.	0.1	0
259	Use of quetiapine in child and adolescent populations – Response to letter from Dr Lambe. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 1084-1085.	1.3	2
260	Child psychopharmacology: how much have we progressed?. <i>World Psychiatry</i> , 2013, 12, 133-134.	4.8	0
261	Pediatric psychopharmacology: too much or too little?. <i>World Psychiatry</i> , 2013, 12, 118-123.	4.8	33
262	Identification and counseling for obesity among children on psychotropic medications in ambulatory settings. <i>Obesity</i> , 2013, 21, 1656-1661.	1.5	4
263	DIFFICULT-TO-TREAT PEDIATRIC OBSESSIVE-COMPULSIVE DISORDER: FEASIBILITY AND PRELIMINARY RESULTS OF A RANDOMIZED PILOT TRIAL OF<sc>d</sc>-CYCLOSERINE-AUGMENTED BEHAVIOR THERAPY. <i>Depression and Anxiety</i> , 2013, 30, 723-731.	2.0	80
264	An Open-Label Extension Study of the Safety and Efficacy of Risperidone in Children and Adolescents with Autistic Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 676-686.	0.7	37
265	Prescribing of psychotropic medications to children and adolescents: <i>quo vadis</i>?. <i>World Psychiatry</i> , 2013, 12, 127-128.	4.8	9

#	ARTICLE	IF	CITATIONS
266	Early Nonresponse Determined by the Clinical Global Impressions Scale Predicts Poorer Outcomes in Youth with Schizophrenia Spectrum Disorders Naturalistically Treated with Second-Generation Antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 665-675.	0.7	30
267	Hematological and Cardiometabolic Safety of Clozapine in the Treatment of Very Early Onset Schizophrenia: A Retrospective Chart Review. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 516-521.	0.7	11
268	Aripiprazole Treatment of Irritability Associated with Autistic Disorder and the Relationship Between Prior Antipsychotic Exposure, Adverse Events, and Weight Change. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 572-576.	0.7	27
269	Safety, Tolerability, and Efficacy of Quetiapine in Youth with Schizophrenia or Bipolar I Disorder: A 26-Week, Open-Label, Continuation Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 490-501.	0.7	22
270	Medication Use in US Youth With Mental Disorders. <i>JAMA Pediatrics</i> , 2013, 167, 141.	3.3	75
271	A Population-Based Study of Antipsychotic Prescription Trends in Children and Adolescents in British Columbia, from 1996 to 2011. <i>Canadian Journal of Psychiatry</i> , 2013, 58, 361-369.	0.9	71
272	759C/T Variants of the Serotonin (5-HT _{2C}) Receptor Gene and Weight Gain in Children and Adolescents in Long-Term Risperidone Treatment. <i>Clinical Pharmacology & Biopharmaceutics</i> , 2013, 02, 110.	0.2	12
273	Atypical Antipsychotics for the Treatment of Disruptive Behavior. <i>Pediatric Annals</i> , 2013, 42, 72-77.	0.3	10
274	When to start aripiprazole therapy in patients with bipolar mania. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 459.	1.0	9
275	Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents. <i>Adolescent Health, Medicine and Therapeutics</i> , 2014, 5, 211.	0.7	10
276	Cardiometabolic Risks of Blonanserin and Perospirone in the Management of Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>PLoS ONE</i> , 2014, 9, e88049.	1.1	19
277	An Evaluation of the Effects of the Novel Antipsychotic Drug Lurasidone on Glucose Tolerance and Insulin Resistance: A Comparison with Olanzapine. <i>PLoS ONE</i> , 2014, 9, e107116.	1.1	18
278	The Antipsychotic Olanzapine Interacts with the Gut Microbiome to Cause Weight Gain in Mouse. <i>PLoS ONE</i> , 2014, 9, e115225.	1.1	147
279	Treatments for Biomedical Abnormalities Associated with Autism Spectrum Disorder. <i>Frontiers in Pediatrics</i> , 2014, 2, 66.	0.9	63
280	Metabolic consequences of second-generation antipsychotics in youth: appropriate monitoring and clinical management. <i>Adolescent Health, Medicine and Therapeutics</i> , 2014, 5, 171.	0.7	10
281	Early prediction of blonanserin response in Japanese patients with schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1861.	1.0	6
282	Pharmacological interventions for reducing weight gain in schizophrenia. <i>The Cochrane Library</i> , 0, , .	1.5	4
283	Cardiometabolic Outcomes in Children and Adolescents Following Discontinuation of Long-Term Risperidone Treatment. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2014, 24, 120-129.	0.7	30

#	ARTICLE	IF	CITATIONS
284	Second-Generation Antipsychotic Use Among Stimulant-Using Children, by Organization of Medicaid Mental Health. <i>Psychiatric Services</i> , 2014, 65, 1458-1464.	1.1	7
285	The use of antipsychotics in preschoolers: A veto or a sensible last option?. <i>Journal of Psychopharmacology</i> , 2014, 28, 303-319.	2.0	14
286	Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial. <i>World Journal of Biological Psychiatry</i> , 2014, 15, 229-241.	1.3	18
287	Age-Related Trends in Psychotropic Medication Use Among Very Young Children in Foster Care. <i>Psychiatric Services</i> , 2014, 65, 1452-1457.	1.1	24
288	Trends in Psychotropic Polypharmacy Among Youths Enrolled in Ohio Medicaid, 2002â€“2008. <i>Psychiatric Services</i> , 2014, 65, 1332-1340.	1.1	42
289	Foster Care, Externalizing Disorders, and Antipsychotic Use Among Medicaid-Enrolled Youths. <i>Psychiatric Services</i> , 2014, 65, 1281-1284.	1.1	32
290	Changes in Physician Antipsychotic Prescribing Preferences, 2002â€“2007. <i>Psychiatric Services</i> , 2014, 65, 315-322.	1.1	25
291	Cardiometabolic health in young people with psychosis. <i>Lancet Psychiatry</i> , the, 2014, 1, 492-494.	3.7	29
292	Adherence to Guidelines for Glucose Assessment in Starting Second-Generation Antipsychotics. <i>Pediatrics</i> , 2014, 134, e1308-e1314.	1.0	36
293	Antipsychotic Polypharmacy in Children and Adolescents at Discharge from Psychiatric Hospitalization. <i>Pharmacotherapy</i> , 2014, 34, 836-844.	1.2	38
294	The 4th Schizophrenia International Research Society Conference, 5â€“9 April 2014, Florence, Italy: A summary of topics and trends. <i>Schizophrenia Research</i> , 2014, 159, e1-e22.	1.1	2
295	Stigma and the perpetuation of obesity. <i>Social Science and Medicine</i> , 2014, 118, 152-158.	1.8	204
297	Progress towards parity: Improving the physical health of long-term psychiatric inpatients. <i>Australian and New Zealand Journal of Psychiatry</i> , 2014, 48, 1060-1061.	1.3	4
298	Quetiapine versus aripiprazole in children and adolescents with psychosis - protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial. <i>BMC Psychiatry</i> , 2014, 14, 199.	1.1	10
299	Psychotropic medication use among children with autism spectrum disorders within the Simons Simplex Collection: Are core features of autism spectrum disorder related?. <i>Autism</i> , 2014, 18, 933-942.	2.4	24
300	Pharmacologic Management of the Agitated Child. <i>Pediatric Emergency Care</i> , 2014, 30, 269-275.	0.5	28
301	Quetiapine Treatment in Youth Is Associated With Decreased Insulin Secretion. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 359-364.	0.7	18
302	Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders. <i>JAMA Psychiatry</i> , 2014, 71, 1350.	6.0	318

#	ARTICLE	IF	CITATIONS
303	Metabolic Monitoring in Commercially Insured Pediatric Patients Newly Initiated to Take a Second-Generation Antipsychotic. <i>JAMA Pediatrics</i> , 2014, 168, 679.	3.3	25
304	Predictors of Polypharmacy and Off-Label Prescribing of Psychotropic Medications. <i>Journal of Psychiatric Practice</i> , 2014, 20, 438-447.	0.3	21
305	DSM-5: Disruptive mood dysregulation disorder. <i>Asian Journal of Psychiatry</i> , 2014, 11, 119-123.	0.9	24
306	Psychotropic Medication Patterns in Medicaid-Insured Youth Based on Clinician-Reported Maltreatment Status. <i>Journal of Child and Family Studies</i> , 2014, 23, 632-640.	0.7	7
307	Trends in Psychotropic Medication Use for Medicaid-Enrolled Preschool Children. <i>Journal of Child and Family Studies</i> , 2014, 23, 617-631.	0.7	18
308	A Review of Recent FDA Drug Safety Communications for Pediatric Psychotropics. <i>Journal of Child and Family Studies</i> , 2014, 23, 716-727.	0.7	5
309	Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges. <i>European Child and Adolescent Psychiatry</i> , 2014, 23, 1149-1160.	2.8	23
310	Management of Adverse Effects of Second-generation Antipsychotics in Youth. <i>Current Treatment Options in Psychiatry</i> , 2014, 1, 84-105.	0.7	12
311	Aripiprazole: A Review of Its Use in the Treatment of Manic Episodes in Adolescents with Bipolar I Disorder. <i>CNS Drugs</i> , 2014, 28, 171-183.	2.7	8
312	Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics. <i>Microbial Biotechnology</i> , 2014, 8, 276-280.	0.9	20
313	Metabolic Effects of Antipsychotics in Prepubertal Children: A Retrospective Chart Review. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2014, 24, 218-222.	0.7	6
314	The Effects of Prior Authorization Policies on Medicaid-Enrolled Children's Use of Antipsychotic Medications: Evidence from Two Mid-Atlantic States. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2014, 24, 374-381.	0.7	31
315	Atypical Antipsychotic Use Among Medicaid-Insured Children and Adolescents: Duration, Safety, and Monitoring Implications. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2014, 24, 112-119.	0.7	46
316	Second-Generation Antipsychotic Use in Children and Adolescents: A Six-Month Prospective Cohort Study in Drug-Naïve Patients. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 1179-1190.e4.	0.3	76
317	Quality Concerns in Antipsychotic Prescribing for Youth: A Review of Treatment Guidelines. <i>Academic Pediatrics</i> , 2014, 14, S68-S75.	1.0	25
318	Growth in the Concurrent Use of Antipsychotics With Other Psychotropic Medications in Medicaid-Enrolled Children. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 960-970.e2.	0.3	53
319	Combination Psychotropic Regimens in Community Practice. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 942-944.	0.3	2
320	Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: A randomized, double-blind, active parallel-controlled, multicenter clinical trial. <i>Schizophrenia Research</i> , 2014, 157, 112-119.	1.1	14

#	ARTICLE	IF	CITATIONS
321	Preliminary and ongoing French multicenter prospective naturalistic study of adverse events of antipsychotic treatment in naive children and adolescents. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2014, 8, 18.	1.2	16
322	SENTIA: a systematic online monitoring registry for children and adolescents treated with antipsychotics. <i>SpringerPlus</i> , 2014, 3, 187.	1.2	10
323	Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12weeks of treatment in first treated episode of psychosis. <i>Schizophrenia Research</i> , 2014, 159, 90-94.	1.1	34
324	The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity. <i>European Journal of Clinical Nutrition</i> , 2014, 68, 146-152.	1.3	55
325	Risk of Diabetes in Children and Adolescents Exposed to Antipsychotics: A Nationwide 12-Year Case-Control Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 971-979.e6.	0.3	22
326	Body Mass Index Change in Autism Spectrum Disorders: Comparison of Treatment with Risperidone and Aripiprazole. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2014, 24, 78-82.	0.7	65
327	Examination of Aggression and Self-injury in Children with Autism Spectrum Disorders and Serious Behavioral Problems. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2014, 23, 57-72.	1.0	47
328	Type and duration of subsyndromal symptoms in youth with bipolar I disorder prior to their first manic episode. <i>Bipolar Disorders</i> , 2014, 16, 478-492.	1.1	91
329	Antipsychotics use in children and adolescents: An on-going challenge in clinical practice. <i>Journal of Psychopharmacology</i> , 2014, 28, 615-623.	2.0	32
330	Obesity Prevention for Children with Developmental Disabilities. <i>Current Obesity Reports</i> , 2014, 3, 156-170.	3.5	66
331	Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 1095-1105.	1.0	45
332	Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Irritability in Autistic Children. <i>Clinical Medicine Insights Pediatrics</i> , 2014, 8, CMPed.S8304.	0.7	21
333	Competent Psychopharmacology. <i>Canadian Journal of Psychiatry</i> , 2014, 59, 406-411.	0.9	16
334	Initial Screening of Children Treated with Second-Generation Antipsychotics Points to an Association between Physical Activity and Insulin Resistance. <i>Pediatric Exercise Science</i> , 2014, 26, 455-462.	0.5	6
335	Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 343-354.	1.0	25
336	Addressing Prediabetes in Childhood Obesity Treatment Programs: Support from Research and Current Practice. <i>Childhood Obesity</i> , 2014, 10, 292-303.	0.8	41
337	Double jeopardy: diabetes and severe mental illness. Addressing the special needs of this vulnerable group. <i>Diabetes Management</i> , 2014, 4, 339-353.	0.5	8
338	Assessing metabolic syndrome in people with ID (intellectual disabilities) on antipsychotic medication. <i>Irish Journal of Psychological Medicine</i> , 2014, 31, 245-251.	0.7	0

#	ARTICLE	IF	CITATIONS
339	Cognitive remediation: potential novel brain-based treatment for bipolar disorder in children and adolescents. <i>CNS Spectrums</i> , 2015, 20, 382-390.	0.7	23
340	Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study. <i>World Psychiatry</i> , 2015, 14, 56-63.	4.8	82
342	Increased Risk of Obesity and Metabolic Dysregulation following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study. <i>Canadian Journal of Psychiatry</i> , 2015, 60, 441-450.	0.9	44
343	Atypical antipsychotic initiation and the risk of type II diabetes in children and adolescents. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 583-591.	0.9	25
344	Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. <i>Acta Psychiatrica Scandinavica</i> , 2015, 132, 97-108.	2.2	216
345	The effect of antidepressants and antipsychotics on weight gain in children and adolescents. <i>Obesity Reviews</i> , 2015, 16, 566-580.	3.1	44
346	Mood Stabilizers in Children and Adolescents With Autism Spectrum Disorders. <i>Clinical Neuropharmacology</i> , 2015, 38, 177-182.	0.2	30
347	Metabolic Impairments Precede Changes in Hunger and Food Intake Following Short-Term Administration of Second-Generation Antipsychotics. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 579-582.	0.7	8
348	First episode affective psychosis and lipid monitoring: survival analysis of the first abnormal lipid test. <i>Microbial Biotechnology</i> , 2015, 9, 507-511.	0.9	3
349	Atypical antipsychotics and metabolic syndrome. <i>Cardiovascular Endocrinology</i> , 2015, 4, 132-137.	0.8	12
350	Using marginal structural models to identify the cardiovascular adverse effects of second generation antipsychotics in children and adolescents. <i>Journal of Epidemiological Research</i> , 2015, 1, 5.	0.6	0
351	Aripiprazole for the management of schizophrenia in the Japanese population: a systematic review and meta-analysis of randomized controlled trials. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 419.	1.0	8
352	Measurement of Metabolic Monitoring in Youth and Adult Medicaid Recipients Prescribed Antipsychotics. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 769-777.	0.5	13
353	Efficacy and Safety of Pharmacological and Psychological Interventions for the Treatment of Psychosis and Schizophrenia in Children, Adolescents and Young Adults: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0117166.	1.1	86
355	Loxapine Add-on for Adolescents and Adults with Autism Spectrum Disorders and Irritability. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 150-159.	0.7	19
356	Risk for Incident Diabetes Mellitus Following Initiation of Second-Generation Antipsychotics Among Medicaid-Enrolled Youths. <i>JAMA Pediatrics</i> , 2015, 169, e150285.	3.3	67
357	Medicaid Prior Authorization Policies for Pediatric Use of Antipsychotic Medications. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 966.	3.8	34
358	Quetiapine and the development of the metabolic syndrome: Table 1. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2015, 108, 245-247.	0.2	4

#	ARTICLE	IF	CITATIONS
359	Obesity and Autism. <i>Pediatrics</i> , 2015, 136, 1051-1061.	1.0	174
360	Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure. <i>EBioMedicine</i> , 2015, 2, 1725-1734.	2.7	116
361	Naturalistic Studies and the Rigor of Psychopharmacology Trials Yet to Come. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 704-705.	0.3	0
362	Changes in Body Mass and Metabolic Profiles in Patients with First-Episode Schizophrenia Treated for 12 Months with A First-Generation Antipsychotic. <i>European Psychiatry</i> , 2015, 30, 277-283.	0.1	28
363	Living with tics: Reduced impairment and improved quality of life for youth with chronic tic disorders. <i>Psychiatry Research</i> , 2015, 225, 571-579.	1.7	66
364	Efficacy and Safety of Paliperidone Extended Release in Adolescents With Schizophrenia: A Randomized, Double-Blind Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 126-137.e1.	0.3	39
365	Use of Quetiapine in Children and Adolescents. <i>Paediatric Drugs</i> , 2015, 17, 125-140.	1.3	25
366	Effectiveness of an Educational Handbook in Improving Psychiatry Resident Knowledge of Second-Generation Antipsychotics. <i>Academic Psychiatry</i> , 2015, 39, 154-159.	0.4	6
367	Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 718-727.e3.	0.3	32
368	Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives. <i>European Neuropsychopharmacology</i> , 2015, 25, 1513-1531.	0.3	56
369	Combined dyslipidemia in childhood. <i>Journal of Clinical Lipidology</i> , 2015, 9, S41-S56.	0.6	42
370	Interaction between the Val158Met catechol-O-methyltransferase gene variant and second-generation antipsychotic treatment on blood pressure in children. <i>Pharmacogenomics Journal</i> , 2015, 15, 95-100.	0.9	7
371	Metabolic side effects and pharmacogenetics of second-generation antipsychotics in children. <i>Pharmacogenomics</i> , 2015, 16, 981-996.	0.6	15
372	An Overview of Links Between Obesity and Mental Health. <i>Current Obesity Reports</i> , 2015, 4, 303-310.	3.5	212
373	Type 2 Diabetes in Children and Adolescents on Atypical Antipsychotics. <i>Current Diabetes Reports</i> , 2015, 15, 53.	1.7	14
374	Adiposity and Cardiometabolic Risk in Children With and Without Antipsychotic Drug Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3418-3426.	1.8	2
375	Treatment of Young People With Antipsychotic Medications in the United States. <i>JAMA Psychiatry</i> , 2015, 72, 867.	6.0	209
376	A Brief History of the Science and Ethics of Antipsychotics and Off-Label Prescribing. , 2015, , 1-12.		1

#	ARTICLE	IF	CITATIONS
377	Ensuring the Safety of Children Treated with Second-Generation Antipsychotics. , 2015, , 65-90.		1
378	Atypical antipsychotics in the treatment of early-onset schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 907.	1.0	12
379	Antipsychotic prescribing in youths: a French community-based study from 2006 to 2013. <i>European Child and Adolescent Psychiatry</i> , 2015, 24, 1181-1191.	2.8	31
380	Individual Dietetic Consultations in First Episode Psychosis: A Novel Intervention to Reduce Cardiometabolic Risk. <i>Community Mental Health Journal</i> , 2015, 51, 211-214.	1.1	14
381	Antipsychotic Cardiometabolic Side Effect Monitoring in a State Community Mental Health System. <i>Community Mental Health Journal</i> , 2015, 51, 685-694.	1.1	19
382	Olanzapine depot exposure in male rats: Dose-dependent lipogenic effects without concomitant weight gain. <i>European Neuropsychopharmacology</i> , 2015, 25, 923-932.	0.3	32
383	Child and Adolescent Psychiatrists' Reported Monitoring Behaviors for Second-Generation Antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 351-361.	0.7	35
384	Genetics in child and adolescent psychiatry: methodological advances and conceptual issues. <i>European Child and Adolescent Psychiatry</i> , 2015, 24, 619-634.	2.8	9
385	Metabolic Monitoring for Youths Initiating Use of Second-Generation Antipsychotics, 2003â€“2011. <i>Psychiatric Services</i> , 2015, 66, 604-609.	1.1	24
386	Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 535-547.	0.7	8
387	Antipsychotic-induced metabolic effects in the female rat: Direct comparison between long-acting injections of risperidone and olanzapine. <i>Journal of Psychopharmacology</i> , 2015, 29, 1280-1289.	2.0	14
388	Metformin in an Adolescent with Significant Weight Gain. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 589-592.	0.7	4
389	Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 482-493.	0.7	61
390	Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children. <i>Translational Psychiatry</i> , 2015, 5, e652-e652.	2.4	154
391	Intervening early in children with bipolar disorder: is there a pot at the end of the Rainbow?. <i>Evidence-Based Mental Health</i> , 2015, 18, 65-66.	2.2	1
392	Major Depressive Disorder and Bipolar Disorder Predispose Youth to Accelerated Atherosclerosis and Early Cardiovascular Disease. <i>Circulation</i> , 2015, 132, 965-986.	1.6	371
393	A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. <i>Schizophrenia Bulletin</i> , 2015, 41, 1227-1236.	2.3	100
394	Long-term effects of prevention and treatment on youth antisocial behavior: A meta-analysis. <i>Clinical Psychology Review</i> , 2015, 42, 130-144.	6.0	63

#	ARTICLE	IF	CITATIONS
395	Childhood obesity in specialist care – searching for a healthy obese child. <i>Annals of Medicine</i> , 2015, 47, 639-654.	1.5	15
396	Change in metabolic parameters and weight in response to risperidone monotherapy in young children with nonpsychotic disorders: a prospective open-label study. <i>Child and Adolescent Mental Health</i> , 2015, 20, 20-25.	1.8	3
398	Diabetes mellitus and severe mental illness: mechanisms and clinical implications. <i>Nature Reviews Endocrinology</i> , 2015, 11, 79-89.	4.3	119
399	Do antipsychotics increase diabetes risk in children and adolescents?. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 219-241.	1.0	29
400	Corrected QT Changes During Antipsychotic Treatment of Children and Adolescents: A Systematic Review and Meta-Analysis of Clinical Trials. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 25-36.	0.3	62
401	Cardiovascular Toxicity as a Result of Psychotropic Drugs. , 2015, , 275-303.		0
402	Prescription Practices in the Treatment of First-Episode Schizophrenia Spectrum Disorders: Data From the National RAISE-ETP Study. <i>American Journal of Psychiatry</i> , 2015, 172, 237-248.	4.0	80
403	Role of Dietary Fatty Acids in Mood Disorders. , 2016, , 423-456.		0
404	A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders. <i>Neuropsychiatric Disease and Treatment</i> , 2016, Volume 12, 3041-3049.	1.0	10
405	Review of Recent Clinical Trials in Schizophrenia. <i>Child and Adolescent Psychopharmacology News</i> , 2016, 21, 1-3,12.	0.1	0
406	The Relationship between Body Weight Change and Body Constitutions of Traditional Chinese Medicine in Patients with Schizophrenia. <i>Evidence-based Complementary and Alternative Medicine</i> , 2016, 2016, 1-9.	0.5	3
408	The interface between medical and psychiatric disorders. , 2015, , 231-241.		2
409	Type 2 Diabetes Mellitus. , 2016, , 255-278.		3
410	Disruptive mood dysregulation disorder: current insights. <i>Neuropsychiatric Disease and Treatment</i> , 2016, Volume 12, 2115-2124.	1.0	42
411	Prediction of early weight gain during psychotropic treatment using a combinatorial model with clinical and genetic markers. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 547-557.	0.7	9
412	Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend Analysis. <i>PLoS ONE</i> , 2016, 11, e0152195.	1.1	3
413	Enteric Ecosystem Disruption in Autism Spectrum Disorder: Can the Microbiota and Macrobiota be Restored?. <i>Current Pharmaceutical Design</i> , 2016, 22, 6107-6121.	0.9	18
414	Elevated triglycerides are associated with decreased executive function among adolescents with bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2016, 134, 241-248.	2.2	46

#	ARTICLE	IF	CITATIONS
415	Integrating Early Intervention for Borderline Personality Disorder and Mood Disorders. <i>Harvard Review of Psychiatry</i> , 2016, 24, 330-341.	0.9	74
416	Weight Gain Effects of Second-Generation Antipsychotic Treatment in Autism Spectrum Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 822-827.	0.7	37
417	Aripiprazole for the treatment of irritability and aggression in children and adolescents affected by autism spectrum disorders. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 867-874.	1.4	17
418	Evaluating an individualized lifestyle and life skills intervention to prevent antipsychotic-induced weight gain in first-episode psychosis. <i>Microbial Biotechnology</i> , 2016, 10, 267-276.	0.9	177
419	Getting to More Effective Weight Management in Antipsychotic-Treated Youth: A Survey of Barriers and Preferences. <i>Childhood Obesity</i> , 2016, 12, 70-76.	0.8	16
420	Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatrists. <i>Italian Journal of Pediatrics</i> , 2016, 42, 51.	1.0	41
421	Digital Parent Training for Children with Disruptive Behaviors: Systematic Review and Meta-Analysis of Randomized Trials. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 740-749.	0.7	88
422	Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2016, 42, 1418-1437.	2.3	149
423	A nutrition intervention is effective in improving dietary components linked to cardiometabolic risk in youth with first-episode psychosis. <i>British Journal of Nutrition</i> , 2016, 115, 1987-1993.	1.2	51
424	A cost-effectiveness analysis of off-label atypical antipsychotic treatment in children and adolescents with ADHD who have failed stimulant therapy. <i>ADHD Attention Deficit and Hyperactivity Disorders</i> , 2016, 8, 149-158.	1.7	5
425	ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 601-614.	1.4	40
426	Antipsychotic Use Trends in Youth With Autism Spectrum Disorder and/or Intellectual Disability: A Meta-Analysis. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016, 55, 456-468.e4.	0.3	57
427	Prevalence of Antidiabetic and Antilipidemic Medications in Children and Adolescents Treated With Atypical Antipsychotics in a Virginia Medicaid Population. <i>Annals of Pharmacotherapy</i> , 2016, 50, 463-470.	0.9	6
428	Challenges and Promises of Pediatric Psychopharmacology. <i>Academic Pediatrics</i> , 2016, 16, 508-518.	1.0	25
429	BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. <i>Journal of Psychopharmacology</i> , 2016, 30, 717-748.	2.0	200
430	Impulsivity is associated with blood pressure and waist circumference among adolescents with bipolar disorder. <i>Journal of Psychiatric Research</i> , 2016, 83, 230-239.	1.5	24
431	Patterns of Antipsychotic Prescribing by Physicians to Young Children. <i>Psychiatric Services</i> , 2016, 67, 1307-1314.	1.1	15
432	Cardiometabolic Risk and Monitoring in Psychiatric Disorders. , 2016, , 305-331.		1

#	ARTICLE	IF	CITATIONS
433	Authors' reply. <i>British Journal of Psychiatry</i> , 2016, 208, 398-399.	1.7	0
434	Antipsychotic prescribing for behavioral disorders in US youth: physician specialty, insurance coverage, and complex regimens. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 26-34.	0.9	21
435	“Mental Health” Power and Its Effects: A Commentary on Battling Against Interfaith Relations in Israel. <i>Journal of Marital and Family Therapy</i> , 2016, 42, 58-61.	0.6	2
436	No Apparent Cardiac Conduction Effects of Acute Treatment with Risperidone in Children with Autism Spectrum Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 900-908.	0.7	7
437	Adjunctive α -lipoic acid reduces weight gain compared with placebo at 12 weeks in schizophrenic patients treated with atypical antipsychotics. <i>International Clinical Psychopharmacology</i> , 2016, 31, 265-274.	0.9	28
439	Identification and Treatment of Pathophysiological Comorbidities of Autism Spectrum Disorder to Achieve Optimal Outcomes. <i>Clinical Medicine Insights Pediatrics</i> , 2016, 10, CMPed.S38337.	0.7	73
440	Aripiprazole for autism spectrum disorders (ASD). <i>The Cochrane Library</i> , 2016, 2016, CD009043.	1.5	92
441	Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 458-470.	0.7	20
442	Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study. <i>Paediatric Drugs</i> , 2016, 18, 319-329.	1.3	26
443	Management of Moderate Hypertriglyceridemia in Childhood and Adolescence. <i>Current Cardiovascular Risk Reports</i> , 2016, 10, 1.	0.8	1
444	Atypical antipsychotics and effects on feeding: from mice to men. <i>Psychopharmacology</i> , 2016, 233, 2629-2653.	1.5	38
445	Morbid obesity and use of second generation antipsychotics among adolescents in foster care: Evidence from Medicaid. <i>Children and Youth Services Review</i> , 2016, 67, 27-31.	1.0	14
446	Physical health and well-being: Experiences and perspectives of young adult mental health consumers. <i>International Journal of Mental Health Nursing</i> , 2016, 25, 299-307.	2.1	18
448	Early psychosis research at Orygen, The National Centre of Excellence in Youth Mental Health. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2016, 51, 1-13.	1.6	31
449	Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics. <i>JAMA Psychiatry</i> , 2016, 73, 247.	6.0	189
450	Topiramate, zonisamide and weight loss in children and adolescents prescribed psychiatric medications. <i>International Journal of Psychiatry in Medicine</i> , 2016, 51, 56-68.	0.8	23
451	Absence of Change in Corrected QT Interval in Children and Adolescents Receiving Antipsychotic Treatment: A 12 Month Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 449-457.	0.7	6
452	Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis. <i>Pediatrics</i> , 2016, 137, S124-S135.	1.0	169

#	ARTICLE	IF	CITATIONS
453	Lurasidone for the Treatment of Irritability Associated with Autistic Disorder. <i>Journal of Autism and Developmental Disorders</i> , 2016, 46, 1153-1163.	1.7	70
454	Impulsive Aggression as a Comorbidity of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 19-25.	0.7	88
455	Aripiprazole Use in Children Diagnosed with Down Syndrome and Comorbid Autism Spectrum Disorders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 306-308.	0.7	5
456	Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis. <i>European Child and Adolescent Psychiatry</i> , 2016, 25, 1091-1102.	2.8	26
457	Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016, 55, 415-423.	0.3	61
458	A meta-analysis of efficacy and safety of aripiprazole in adult and pediatric bipolar disorder in randomized controlled trials and observational studies. <i>Journal of Affective Disorders</i> , 2016, 191, 187-208.	2.0	21
459	Barriers and facilitators of obesity management in families of youth with emotional and behavioral disorders. <i>Journal of Health Psychology</i> , 2017, 22, 1469-1479.	1.3	7
460	Challenges in developing drugs for pediatric CNS disorders: A focus on psychopharmacology. <i>Progress in Neurobiology</i> , 2017, 152, 38-57.	2.8	17
461	The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study. <i>European Child and Adolescent Psychiatry</i> , 2017, 26, 35-46.	2.8	43
462	Body composition, pre-diabetes and cardiovascular disease risk in early schizophrenia. <i>Microbial Biotechnology</i> , 2017, 11, 229-236.	0.9	16
463	Predictors of favourable outcome in young people with a first episode psychosis without antipsychotic medication. <i>Schizophrenia Research</i> , 2017, 185, 130-136.	1.1	19
464	Examining psychotropic medication use among youth in the U.S. by race/ethnicity and psychological impairment. <i>General Hospital Psychiatry</i> , 2017, 45, 32-39.	1.2	22
465	Second-Generation Antipsychotic Utilization and Metabolic Parameter Monitoring in an Inpatient Pediatric Population: A Retrospective Analysis. <i>Paediatric Drugs</i> , 2017, 19, 139-146.	1.3	6
466	Risperidone and Cardiometabolic Risk in Children and Adolescents. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 302-309.	0.7	5
467	Concomitant Use of Atypical Antipsychotics With Other Psychotropic Medication Classes and the Risk of Type 2 Diabetes Mellitus. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2017, 56, 642-651.	0.3	36
468	Transformation of excess mortality in people with schizophrenia and bipolar disorder in Taiwan. <i>Psychological Medicine</i> , 2017, 47, 2483-2493.	2.7	15
469	Different Immune Signature in Youths Experiencing Antipsychotic-Induced Weight Gain Compared to Untreated Obese Patients. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 844-848.	0.7	9
470	Investigational dopamine antagonists for the treatment of schizophrenia. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 687-698.	1.9	18

#	ARTICLE	IF	CITATIONS
471	TOX and ADIPOQ Gene Polymorphisms Are Associated with Antipsychotic-Induced Weight Gain in Han Chinese. <i>Scientific Reports</i> , 2017, 7, 45203.	1.6	13
472	Dopamine antagonists for treatment resistance in autism spectrum disorders: review and focus on BDNF stimulators loxapine and amitriptyline. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 581-588.	0.9	28
473	Changes in BMI in hospitalized patients during treatment with antipsychotics, depending on gender and other factors. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017, 21, 112-117.	1.2	11
474	Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria. <i>Therapeutic Advances in Psychopharmacology</i> , 2017, 7, 1-14.	1.2	20
475	A developmental approach to dimensional expression of psychopathology in child and adolescent offspring of parents with bipolar disorder. <i>European Child and Adolescent Psychiatry</i> , 2017, 26, 1165-1175.	2.8	10
476	Decrease in Statewide Antipsychotic Prescribing after Implementation of Child and Adolescent Psychiatry Consultation Services. <i>Health Services Research</i> , 2017, 52, 561-578.	1.0	35
477	Advancing the Quality of Pediatric Antipsychotic Use: Maybe It Takes a PAL. <i>Health Services Research</i> , 2017, 52, 555-560.	1.0	4
478	Psychiatric diagnoses and medication treatment among patients presenting for paediatric weight management: associations with adiposity, aerobic fitness and cardiometabolic health. <i>Clinical Obesity</i> , 2017, 7, 145-150.	1.1	3
479	Solving a weighty problem: Systematic review and meta-analysis of nutrition interventions in severe mental illness. <i>British Journal of Psychiatry</i> , 2017, 210, 110-118.	1.7	153
480	Psychotropic medications prescribing trends in adolescents: A nationwide population-based study in Taiwan. <i>International Journal for Quality in Health Care</i> , 2017, 29, 861-866.	0.9	15
481	Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2017, 56, 1015-1025.	0.3	79
482	Improving Cardiometabolic Monitoring of Children on Antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 916-919.	0.7	15
483	Feasibility and Relevance of Antipsychotic Safety Monitoring in Children With Tourette Syndrome. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 498-504.	0.7	21
484	Improving metabolic monitoring rate for young people aged 35 and younger taking antipsychotic medications to treat a psychosis: A literature review. <i>Archives of Psychiatric Nursing</i> , 2017, 31, 624-633.	0.7	6
485	Improved Metabolic and Psychiatric Outcomes with Discontinuation of Atypical Antipsychotics in Youth Hospitalized in a State Psychiatric Facility. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 897-907.	0.7	5
486	An Investigation of Cardiovascular Risks in a Group of Children and Adolescents Who Use Atypical Antipsychotics. <i>Issues in Mental Health Nursing</i> , 2017, 38, 872-880.	0.6	1
487	Prescribing trends and indications of antipsychotic medication in Hong Kong from 2004 to 2014: General and vulnerable patient groups. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1387-1394.	0.9	29
488	Polypharmacy in Youth Treated With Antipsychotics: Do Antidepressants or Stimulants Add to the Risk for Type 2 Diabetes?. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2017, 56, 634-635.	0.3	4

#	ARTICLE	IF	CITATIONS
490	Atypical antipsychotics for disruptive behaviour disorders in children and youths. The Cochrane Library, 2017, 2017, CD008559.	1.5	65
491	Prevalence and Risk Factors of Prolonged Corrected QT Interval Among Children and Adolescents Treated With Antipsychotic Medications. Journal of Clinical Psychopharmacology, 2017, 37, 78-83.	0.7	15
492	Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2017, 56, 784-792.	0.3	21
493	Pediatric Motor Stereotypies: An Updated Review. Journal of Pediatric Neurology, 2017, 15, 151-156.	0.0	3
494	Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options. Journal of Endocrinological Investigation, 2017, 40, 1165-1174.	1.8	51
495	Trajectories of body mass index change in first episode of mania: 3-year data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). Journal of Affective Disorders, 2017, 208, 291-297.	2.0	20
496	Neuroadaptations to antipsychotic drugs: Insights from pre-clinical and human post-mortem studies. Neuroscience and Biobehavioral Reviews, 2017, 76, 317-335.	2.9	31
497	Trends in Antipsychotic Prescribing in Medicaid-Eligible Youth. Journal of the American Academy of Child and Adolescent Psychiatry, 2017, 56, 59-66.	0.3	39
498	Risperidone Added to Psychostimulant in Children with Severe Aggression and Attention-Deficit/Hyperactivity Disorder: Lack of Effect on Attention and Short-Term Memory. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 117-124.	0.7	8
499	Cardiometabolic risk in first-episode schizophrenia (FES) patients with the earliest stages of both illness and antipsychotic treatment. Schizophrenia Research, 2017, 179, 41-49.	1.1	20
500	The Validity and Reliability Characteristics of the M-BACK Questionnaire to Assess the Barriers, Attitudes, Confidence, and Knowledge of Mental Health Staff Regarding Metabolic Health of Mental Health Service Users. Frontiers in Public Health, 2017, 5, 321.	1.3	14
501	Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 2231-2241.	1.0	196
502	Cardiovascular disease in patients with schizophrenia. Medical Journal of Australia, 2017, 206, 91-95.	0.8	51
503	Can melatonin prevent or improve metabolic side effects during antipsychotic treatments?. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 2167-2174.	1.0	22
504	A multi-national comparison of antipsychotic drug use in children and adolescents, 2005â€“2012. Child and Adolescent Psychiatry and Mental Health, 2017, 11, 55.	1.2	54
505	A case of a four-year-old child adopted at eight months with unusual mood patterns and significant polypharmacy. BMC Psychiatry, 2017, 17, 330.	1.1	2
506	Psychotropic Medication Patterns for American Indian Children in Foster Care. Journal of Child and Adolescent Psychopharmacology, 2018, 28, 225-231.	0.7	6
507	Cardiometabolic risks and omegaâ€“3 index in recentâ€“onset bipolar I disorder. Bipolar Disorders, 2018, 20, 658-665.	1.1	11

#	ARTICLE	IF	CITATIONS
508	Differences in Metabolic Factors Between Antipsychotic-Induced Weight Gain and Non-pharmacological Obesity in Youths. <i>Clinical Drug Investigation</i> , 2018, 38, 457-462.	1.1	9
509	Case study of an adaptation and implementation of a Diabetes Prevention Program for individuals with serious mental illness. <i>Translational Behavioral Medicine</i> , 2018, 8, 195-203.	1.2	11
510	Symptom Profiles and Mental Health Services Received Among Referred Adolescents. <i>School Mental Health</i> , 2018, 10, 96-110.	1.1	13
511	Childhood and Adolescent Adversity and Cardiometabolic Outcomes: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2018, 137, e15-e28.	1.6	313
512	Family-Based Behavioral Interventions for Childhood Obesity. <i>Contemporary Endocrinology</i> , 2018, , 555-567.	0.3	3
513	Effects of physical activity on the symptoms of Tourette syndrome: A systematic review. <i>European Psychiatry</i> , 2018, 48, 13-19.	0.1	18
514	Second-Generation Antipsychotics in Adolescent Psychiatric Patients: Metabolic Effects and Impact of an Early Weight Change to Predict Longer Term Weight Gain. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 258-265.	0.7	13
515	Prevention and Treatment of Obesity and Metabolic Dysfunction in Children with Major Behavioral Disorders: Second-Generation Antipsychotics. <i>Contemporary Endocrinology</i> , 2018, , 643-659.	0.3	0
516	Inconsistencies in dosage practice in children with overweight or obesity: A retrospective cohort study. <i>Pharmacology Research and Perspectives</i> , 2018, 6, e00398.	1.1	14
517	Patient, Treatment, and Health Care Utilization Variables Associated with Adherence to Metabolic Monitoring Practices in Children and Adolescents Taking Second-Generation Antipsychotics. <i>Canadian Journal of Psychiatry</i> , 2018, 63, 240-249.	0.9	22
518	Mechanisms in endocrinology: Antipsychotic medication and type 2 diabetes and impaired glucose regulation. <i>European Journal of Endocrinology</i> , 2018, 178, R245-R258.	1.9	33
519	Psychotropic Polypharmacy Among Youths With Serious Emotional and Behavioral Disorders Receiving Coordinated Care Services. <i>Psychiatric Services</i> , 2018, 69, 716-722.	1.1	15
520	Monitoring of physical health in services for young people at ultra-high risk of psychosis. <i>Microbial Biotechnology</i> , 2018, 12, 153-159.	0.9	26
521	Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial. <i>Molecular Psychiatry</i> , 2018, 23, 247-256.	4.1	143
522	Impact of nurse-led behavioural counselling to improve metabolic health and physical activity among adults with mental illness. <i>International Journal of Mental Health Nursing</i> , 2018, 27, 619-630.	2.1	7
523	Overweight and obese status in children with autism spectrum disorder and disruptive behavior. <i>Autism</i> , 2018, 22, 450-459.	2.4	53
524	Providers' Behaviors and Beliefs on Prescribing Antipsychotic Medication to Children: A Qualitative Study. <i>Community Mental Health Journal</i> , 2018, 54, 17-26.	1.1	6
525	Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis. <i>Schizophrenia Research</i> , 2018, 193, 188-196.	1.1	50

#	ARTICLE	IF	CITATIONS
526	Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis. <i>Schizophrenia Research</i> , 2018, 195, 231-236.	1.1	49
527	Diabetes Screening among Antipsychotic-Treated Adults with Severe Mental Illness in an Integrated Delivery System: A Retrospective Cohort Study. <i>Journal of General Internal Medicine</i> , 2018, 33, 79-86.	1.3	17
528	Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis. <i>Psychopharmacology</i> , 2018, 235, 245-255.	1.5	30
529	Adolescents at ultra-high risk of psychosis in Italian neuropsychiatry services: prevalence, psychopathology and transition rate. <i>European Child and Adolescent Psychiatry</i> , 2018, 27, 725-737.	2.8	41
530	A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers. <i>Schizophrenia Research</i> , 2018, 195, 245-251.	1.1	42
531	Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia. <i>Journal of Clinical Lipidology</i> , 2018, 12, 219-229.	0.6	15
532	Asenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review. <i>Paediatric Drugs</i> , 2018, 20, 121-134.	1.3	9
533	Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial. <i>Psychopharmacology</i> , 2018, 235, 681-693.	1.5	7
534	Clinical and demographic predictors of continuing remission or relapse following discontinuation of antipsychotic medication after a first episode of psychosis. A systematic review. <i>Schizophrenia Research</i> , 2018, 197, 9-18.	1.1	51
535	Diet and cardiometabolic side effects in children treated with second-generation antipsychotics. <i>Clinical Nutrition ESPEN</i> , 2018, 23, 205-211.	0.5	14
536	Monitoring and Treating Metabolic Abnormalities in Patients with Early Psychosis Initiated on Antipsychotic Medications. <i>Community Mental Health Journal</i> , 2018, 54, 717-724.	1.1	10
537	Impact of Coordinated Behavioral Health Management on Quality Measures of Antipsychotic Use. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 2018, 45, 174-185.	1.2	7
538	Effects of the First Exposure of Antipsychotics on Serum Albumin in Adolescents and Young Adults With First-Episode Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 103-105.	0.7	5
539	Risperidone But Not Quetiapine Treatment Is Associated With Increased Appetite But Not Satiety Hormones in Children During An Oral Glucose Tolerance Test. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 622-626.	0.7	2
540	Hormonal Risk Factors for Osteoporosis: Different Profile Among Antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 719-726.	0.7	7
541	Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2018, 9, 622.	1.3	115
542	Metformin for Weight Gain Associated with Second-Generation Antipsychotics in Children and Adolescents: A Systematic Review and Meta-Analysis. <i>CNS Drugs</i> , 2018, 32, 1103-1112.	2.7	34
543	Pediatric Obesity: Influence on Drug Dosing and Therapeutics. <i>Journal of Clinical Pharmacology</i> , 2018, 58, S94-S107.	1.0	14

#	ARTICLE	IF	CITATIONS
544	Neuroleptic Prescribing and Monitoring Practices in Pediatric Inpatient Medical and Psychiatric Settings. <i>Hospital Pediatrics</i> , 2018, 8, 410-418.	0.6	6
545	Olanzapine for chemotherapy-induced nausea: Lessons learned from child and adolescent psychiatry. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27289.	0.8	11
546	Psychological interventions in offspring of parents with bipolar disorder. , 2018, , 247-264.		1
547	Use of Academic Detailing With Audit and Feedback to Improve Antipsychotic Pharmacotherapy. <i>Psychiatric Services</i> , 2018, 69, 1021-1028.	1.1	6
548	Psychotropic Polypharmacy Among Children and Youth Receiving Medicaid, 2012-2015. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 736-744.	0.5	27
549	Differences in Medicaid Antipsychotic Medication Measures Among Children with SSI, Foster Care, and Income-Based Aid. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 238-246.	0.5	25
550	The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment. <i>Frontiers in Neuroscience</i> , 2017, 11, 741.	1.4	78
551	One-Year Prospective Study of Liver Function Tests in Children and Adolescents on Second-Generation Antipsychotics: Is There a Link with Metabolic Syndrome?. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 463-473.	0.7	6
552	Psychotropic medication in children and adolescents in the United States in the year 2004 vs 2014. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2018, 26, 5-10.	0.9	26
553	Cardiovascular Events Following Treatment Initiation with Atypical Antipsychotic Medications in Publicly Insured U.S. Youth. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 445-453.	0.7	5
554	Family- and community-based treatments. , 2018, , 263-295.		0
555	Social Skills Deficits in Autism Spectrum Disorder: Potential Biological Origins and Progress in Developing Therapeutic Agents. <i>CNS Drugs</i> , 2018, 32, 713-734.	2.7	84
556	Harms of Antipsychotics in Children and Young Adults: A Systematic Review Update. <i>Canadian Journal of Psychiatry</i> , 2018, 63, 661-678.	0.9	27
557	Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths. <i>JAMA Psychiatry</i> , 2018, 75, 788.	6.0	54
558	Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 474-484.	0.7	21
559	Cardiovascular Safety of Psychiatric Agents: A Cautionary Tale. <i>Angiology</i> , 2019, 70, 103-129.	0.8	20
560	Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia. <i>CNS Spectrums</i> , 2019, 24, 395-403.	0.7	15
561	Striatal volume and functional connectivity correlate with weight gain in early-phase psychosis. <i>Neuropsychopharmacology</i> , 2019, 44, 1948-1954.	2.8	16

#	ARTICLE	IF	CITATIONS
562	Study protocol for a randomised controlled trial of CBT vs antipsychotics vs both in 14-18-year-olds: Managing Adolescent first episode Psychosis: a feasibility study (MAPS). <i>Trials</i> , 2019, 20, 395.	0.7	11
563	Incidence of adverse events in antipsychotic-naïve children and adolescents treated with antipsychotic drugs: Results of a multicenter naturalistic study (ETAPE). <i>European Neuropsychopharmacology</i> , 2019, 29, 1397-1407.	0.3	14
564	Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain. <i>Cells</i> , 2019, 8, 1336.	1.8	92
565	Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. <i>CNS Spectrums</i> , 2019, 24, 38-69.	0.7	87
566	An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes. <i>Journal of Psychopharmacology</i> , 2019, 33, 1227-1236.	2.0	24
567	Obesity in Adolescents with Psychiatric Disorders. <i>Current Psychiatry Reports</i> , 2019, 21, 3.	2.1	49
568	Neurofeedback for Pediatric Emotional Dysregulation. , 2019, , 277-311.		0
569	Aripiprazole compared with placebo for auditory verbal hallucinations in youth with borderline personality disorder: Protocol for the VERBATIM randomized controlled trial. <i>Microbial Biotechnology</i> , 2019, 13, 1373-1381.	0.9	10
570	CYP2D6 genotype and adverse events to risperidone in children and adolescents. <i>Pediatric Research</i> , 2019, 85, 602-606.	1.1	21
571	No Differences in Weight Gain Between Risperidone and Aripiprazole in Children and Adolescents After 12 Months. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 192-196.	0.7	17
572	Antipsychotics Promote Metabolic Disorders Disrupting Cellular Lipid Metabolism and Trafficking. <i>Trends in Endocrinology and Metabolism</i> , 2019, 30, 189-210.	3.1	30
573	Antipsychotics differentially regulate insulin, energy sensing, and inflammation pathways in hypothalamic rat neurons. <i>Psychoneuroendocrinology</i> , 2019, 104, 42-48.	1.3	33
574	The effects of antipsychotic medications on microbiome and weight gain in children and adolescents. <i>BMC Medicine</i> , 2019, 17, 112.	2.3	58
575	What is the prevalence, and what are the clinical correlates, of insulin resistance in young people presenting for mental health care? A cross-sectional study. <i>BMJ Open</i> , 2019, 9, e025674.	0.8	13
576	Sex differences in gene expression related to antipsychotic induced weight gain. <i>PLoS ONE</i> , 2019, 14, e0215477.	1.1	13
577	Adiposity, Hepatic Triglyceride, and Carotid Intima Media Thickness During Behavioral Weight Loss Treatment in Antipsychotic-Treated Youth: A Randomized Pilot Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 439-447.	0.7	10
578	Altered gene expression in antipsychotic-induced weight gain. <i>NPJ Schizophrenia</i> , 2019, 5, 7.	2.0	16
579	Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2019, 58, 1062-1078.	0.3	16

#	ARTICLE	IF	CITATIONS
580	Rating of the Effectiveness of 26 Psychiatric and Seizure Medications for Autism Spectrum Disorder: Results of a National Survey. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 107-123.	0.7	45
581	Assessing provider and racial/ethnic variation in response to the <sc>FDA</sc> antidepressant box warning. <i>Health Services Research</i> , 2019, 54, 255-262.	1.0	8
582	Dietary intake of people with severe mental illness: systematic review and meta-analysis. <i>British Journal of Psychiatry</i> , 2019, 214, 251-259.	1.7	160
583	Clinical Characteristics, Drug Adherence to Antipsychotics and Medical Use Trends in Patients First Diagnosed with Psychotic Disorder: A Preliminary Study. <i>Korean Journal of Schizophrenia Research</i> , 2019, 22, 42.	0.3	3
584	Pharmacological interventions for reduction of weight gain in people with schizophrenia. <i>The Cochrane Library</i> , 2019, , .	1.5	0
585	Pharmacological interventions for prevention of weight gain in people with schizophrenia. <i>The Cochrane Library</i> , 2019, , .	1.5	0
586	A prospective study of adverse effects of antipsychotics in adolescents with schizophrenia during a 6-month follow-up. <i>International Clinical Psychopharmacology</i> , 2019, 34, 33-36.	0.9	1
587	Cross-species examination of single- and multi-strain probiotic treatment effects on neuropsychiatric outcomes. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 99, 160-197.	2.9	12
588	Weight-Change Trajectories of Pediatric Outpatients Treated with Risperidone or Aripiprazole in a Naturalistic Setting. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 133-140.	0.7	14
589	Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants. <i>Microbial Biotechnology</i> , 2019, 13, 953-960.	0.9	19
590	Should people with psychosis be supported in choosing cognitive therapy as an alternative to antipsychotic medication: A commentary on current evidence. <i>Schizophrenia Research</i> , 2019, 203, 94-98.	1.1	11
591	Brain insulin action: Implications for the treatment of schizophrenia. <i>Neuropharmacology</i> , 2020, 168, 107655.	2.0	19
592	Molecular pathway analysis associates alterations in obesity-related genes and antipsychotic-induced weight gain. <i>Acta Neuropsychiatrica</i> , 2020, 32, 72-83.	1.0	13
593	Prevalence of obesity, metabolic syndrome, diabetes and risk of cardiovascular disease in a psychiatric inpatient sample: results of the Metabolism in Psychiatry (MiP) Study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 597-609.	1.8	20
594	Psychopharmacologic Treatment of Schizophrenia in Adolescents and Children. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2020, 29, 183-210.	1.0	16
595	Metformin addition vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. <i>World Psychiatry</i> , 2020, 19, 69-80.	4.8	68
596	Keeping the body in mind: A qualitative analysis of the experiences of people experiencing first-episode psychosis participating in a lifestyle intervention programme. <i>International Journal of Mental Health Nursing</i> , 2020, 29, 278-289.	2.1	21
597	Care Management for Youth With Comorbid Developmental and Mental Health Conditions: A Discrete Choice Experiment Pilot Study. <i>Academic Pediatrics</i> , 2020, 20, 241-249.	1.0	2

#	ARTICLE	IF	CITATIONS
598	Paper based vs. electronic records for clinical audit: Evidence of documentation of medication safety monitoring in youth prescribed antipsychotics. <i>Children and Youth Services Review</i> , 2020, 109, 104666.	1.0	1
599	Metabolic Monitoring of Child and Adolescent Patients on Atypical Antipsychotics by Psychiatrists and Primary Care Providers. <i>American Journal of Therapeutics</i> , 2020, 27, e425-e430.	0.5	13
600	Cariprazine in Youth with Bipolar and Psychotic Disorders: A Retrospective Chart Review. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020, 30, 267-272.	0.7	4
601	Safety and effectiveness of lurasidone in adolescents with schizophrenia: results of a 2-year, open-label extension study. <i>CNS Spectrums</i> , 2022, 27, 118-128.	0.7	11
602	Pharmacotherapy of attention-deficit hyperactivity disorder: common quandaries, dilemmas and challenges. <i>International Clinical Psychopharmacology</i> , 2020, 35, 300-304.	0.9	1
603	Metabolic events associated with the use of antipsychotics in children, adolescents and young adults: a multinational sequence symmetry study. <i>European Child and Adolescent Psychiatry</i> , 2020, , 1.	2.8	8
604	<p>Pharmacological Intervention in Children with Autism Spectrum Disorder with Standard Supportive Therapies Significantly Improves Core Signs and Symptoms: A Single-Center, Retrospective Case Series</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 2779-2794.	1.0	9
605	Attitudes to physical healthcare in severe mental illness; a patient and mental health clinician qualitative interview study. <i>BMC Family Practice</i> , 2020, 21, 243.	2.9	17
606	Risperidone-Induced Obesity in Children and Adolescents With Autism Spectrum Disorder: Genetic and Clinical Risk Factors. <i>Frontiers in Pharmacology</i> , 2020, 11, 565074.	1.6	10
607	Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study. <i>Lancet Psychiatry</i> ,the, 2020, 7, 788-800.	3.7	51
608	Weight gain and metabolic screening in young people with early psychosis on long acting injectable antipsychotic medication (aripiprazole vs paliperidone). <i>Microbial Biotechnology</i> , 2021, 15, 787-793.	0.9	10
609	Management of Complex Co-occurring Psychiatric Disorders and High-Risk Behaviors in Adolescence. <i>Focus (American Psychiatric Publishing)</i> , 2020, 18, 139-149.	0.4	3
610	Risk factors and pattern of weight gain in youths using antipsychotic drugs. <i>European Child and Adolescent Psychiatry</i> , 2021, 30, 1263-1271.	2.8	14
611	Integrative Management of Metabolic Syndrome in Youth Prescribed Second-Generation Antipsychotics. <i>Medical Sciences (Basel, Switzerland)</i> , 2020, 8, 34.	1.3	1
612	Long-Term Metabolic Monitoring of Youths Treated with Second-Generation Antipsychotics 5 Years after Publication of the CAMESA Guidelines Are We Making Progress? Surveillance MÃ©tabolique Ã Long Terme des Jeunes TraitÃ©s par Antipsychotiques de DeuxiÃ©me GÃ©nÃ©ration, Cinq ans AprÃ©s la publication des Lignes Directrices Camesa: Faisons-Nous des ProgrÃ©s?. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 645-656.	0.9	6
613	The Psychology of Food Cravings in Patients With First-Episode Psychosis. <i>Frontiers in Psychiatry</i> , 2020, 11, 587486.	1.3	5
614	We Really Need Clear Guidelines and Recommendations for Safer and Proper Use of Aripiprazole and Risperidone in a Pediatric Population: Real-World Analysis of EudraVigilance Database. <i>Frontiers in Psychiatry</i> , 2020, 11, 550201.	1.3	10
615	Preclinical atherosclerosis in adolescents with psychotic or bipolar disorders investigated with carotid high-frequency ultrasound. <i>Brain and Behavior</i> , 2020, 10, e01862.	1.0	8

#	ARTICLE	IF	CITATIONS
616	Understanding Mechanisms Underlying Non-Alcoholic Fatty Liver Disease (NAFLD) in Mental Illness: Risperidone and Olanzapine Alter the Hepatic Proteomic Signature in Mice. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9362.	1.8	16
617	New Users of Antipsychotics Among Children and Adolescents in 2008–2017: A Nationwide Register Study. <i>Frontiers in Psychiatry</i> , 2020, 11, 316.	1.3	14
618	Antipsychotics, Weight Gain and Metabolic Risk. , 2020, , 619-619.		0
619	Increased Appetite Plays a Key Role in Olanzapine-Induced Weight Gain in First-Episode Schizophrenia Patients. <i>Frontiers in Pharmacology</i> , 2020, 11, 739.	1.6	25
621	Spillover effects of state medicaid antipsychotic prior authorization policies in <scp>US commercially insured</scp> youth. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1064-1071.	0.9	4
622	Weight and body mass index increase in children and adolescents exposed to antipsychotic drugs in non-interventional settings: a meta-analysis and meta-regression. <i>European Child and Adolescent Psychiatry</i> , 2022, 31, 21-37.	2.8	11
623	Olanzapine, risperidone, and aripiprazole use in children and adolescents with Autism Spectrum Disorders. <i>Research in Autism Spectrum Disorders</i> , 2020, 72, 101520.	0.8	19
624	Association between the -2548G/A polymorphism of the leptin gene and antipsychotic-induced weight gain: Analysis of the CATIE sample and meta-analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 102, 109952.	2.5	8
625	Safety and Tolerability of Antipsychotic Drugs in Pediatric Patients: Data From a 1-Year Naturalistic Study. <i>Frontiers in Psychiatry</i> , 2020, 11, 152.	1.3	13
626	Meta-analysis: Pharmacologic Treatment of Restricted and Repetitive Behaviors in Autism Spectrum Disorders. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2021, 60, 35-45.	0.3	55
627	Comparative cardiometabolic risk of antipsychotics in children, adolescents and young adults. <i>European Child and Adolescent Psychiatry</i> , 2021, 30, 769-783.	2.8	4
628	Lumateperone: A Novel Antipsychotic for Schizophrenia. <i>Annals of Pharmacotherapy</i> , 2021, 55, 98-104.	0.9	28
629	Prevalence of obesity and clinical and metabolic correlates in first-episode schizophrenia relative to healthy controls. <i>Psychopharmacology</i> , 2021, 238, 745-753.	1.5	18
630	Greater Arterial Stiffness in Children with or without Second-generation Antipsychotic Treatment for Mental Health Disorders: Rigidité Artérielle Plus Importante Chez Les Enfants Avec ou Sans Traitement Par Antipsychotiques de la Deuxième Génération Pour des Troubles de Santé Mentale. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 667-676.	0.9	2
631	Impact of Antipsychotic Guidelines on Laboratory Monitoring in Children with Neurodevelopmental Disorders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021, 31, 79-83.	0.7	6
632	Analysis of the status of drug treatment in 746 inpatients with early-onset schizophrenia in China: a retrospective study. <i>BMC Psychiatry</i> , 2021, 21, 10.	1.1	0
633	Çocuk ve ergen psikiyatri polikliniğine başvuran olguların beden kitle indeksi, beslenme tutum ve davranışları: duygusal ve davranışsal sorunlarla ilişkisi. <i>Pamukkale Medical Journal</i> , 0, , .	0.2	1
634	Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies. <i>European Psychiatry</i> , 2021, 64, e35.	0.1	8

#	ARTICLE	IF	CITATIONS
635	Acetylcholinesterase inhibitors and risk of bleeding and acute ischemic events in non-hypertensive Alzheimer's patients. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12184.	1.8	2
636	The Biology of Vasopressin. <i>Biomedicines</i> , 2021, 9, 89.	1.4	29
637	Does Switching Antipsychotics Ameliorate Weight Gain in Patients With Severe Mental Illness? A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2021, 47, 948-958.	2.3	26
638	Getting to Precision Psychopharmacology in Child Psychiatry: The Value of Adverse Treatment Effects. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021, 31, 1-3.	0.7	2
640	Stepped Treatment for Attention-Deficit/Hyperactivity Disorder and Aggressive Behavior: A Randomized, Controlled Trial of Adjunctive Risperidone, Divalproex Sodium, or Placebo After Stimulant Medication Optimization. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2021, 60, 236-251.	0.3	42
641	"Listen to the parents" really listen to the child! Family narratives of supporting children hearing voices. <i>Psychosis</i> , 2021, 13, 209-219.	0.4	2
642	Treatment-related weight gain and metabolic complications in children with mental health disorders: potential role for lifestyle interventions. <i>Applied Physiology, Nutrition and Metabolism</i> , 2021, 46, 193-204.	0.9	5
643	The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children. <i>Frontiers in Psychiatry</i> , 2021, 12, 623681.	1.3	44
644	Second-Generation Antipsychotic Use in Pediatric Emergency Medicine. <i>Pediatric Emergency Care</i> , 2021, 37, 161-164.	0.5	1
645	Psychiatric Prescribing in Child Welfare: Barriers to Evidence-Based Practice and an Agenda for Reform. <i>Child and Adolescent Social Work Journal</i> , 0, , 1.	0.7	0
646	Risperidone or Aripiprazole Can Resolve Autism Core Signs and Symptoms in Young Children: Case Study. <i>Children</i> , 2021, 8, 318.	0.6	9
647	Body mass index increase in preschoolers with heterogeneous psychiatric diagnoses treated with risperidone. <i>Journal of Psychopharmacology</i> , 2021, 35, 1134-1140.	2.0	2
648	Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial. <i>Translational Psychiatry</i> , 2021, 11, 219.	2.4	14
649	Low Rates of Clinician Monitoring for Second Generation Antipsychotic Medications in Community Pediatric Practice. <i>Community Mental Health Journal</i> , 2021, , 1.	1.1	1
650	Systematic Review and Network Meta-analysis: Efficacy and Safety of Second-Generation Antipsychotics in Youths With Bipolar Depression. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2022, 61, 243-254.	0.3	12
651	Current strategies for predicting side effects from second generation antipsychotics in youth. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 655-664.	1.5	3
652	Development of a Symptom-Focused Model to Guide the Prescribing of Antipsychotics in Children and Adolescents: Results of the First Phase of the Safer and Targeted Use of Antipsychotics (SUAY) Clinical Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2021, , .	0.3	6
653	High-level psychotropic polypharmacy: a retrospective comparison of children in foster care to their peers on Medicaid. <i>BMC Psychiatry</i> , 2021, 21, 303.	1.1	9

#	ARTICLE	IF	CITATIONS
654	Antipsychotics in Inpatient Children and Adolescents with Seclusion and Restraint: A Preliminary Exploratory Retrospective Chart Review. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021, 31, 358-363.	0.7	1
655	Effect of an online healthy lifestyle psychoeducation programme to improve cardiometabolic outcomes and affective symptoms in youth receiving mental health care: study protocol for a pilot clinical trial. <i>BMJ Open</i> , 2021, 11, e044977.	0.8	2
656	Systematic Quality Improvement and Metabolic Monitoring for Individuals Taking Antipsychotic Drugs. <i>Psychiatric Services</i> , 2021, 72, 647-653.	1.1	4
657	Dietary Consumption Among Youth with Antipsychotic-Induced Weight Gain and Changes Following Healthy Lifestyle Education. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021, 31, 364-375.	0.7	4
658	Unveiling the Metabolic Profile of First-Episode Drug-Naïve Schizophrenia Patients: Baseline Characteristics of a Longitudinal Study Among Han Chinese. <i>Frontiers in Psychiatry</i> , 2021, 12, 702720.	1.3	4
659	The prevalence and risk factors for overweight/obesity among Turkish children with neurodevelopmental disorders. <i>Research in Developmental Disabilities</i> , 2021, 114, 103992.	1.2	5
660	Risk of Obesity Among Children Prescribed Atypical Antipsychotics for Six Months or More. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2022, 32, 52-60.	0.7	7
661	Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis. <i>Neuropsychopharmacology</i> , 2022, 47, 664-672.	2.8	19
662	Trends in off-label use of antipsychotic medications among Texas Medicaid children and adolescents from 2013 to 2016. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1035-1045.	0.5	6
663	Weight gain on antipsychotics – A perfect storm of complex pathophysiology and psychopharmacology. <i>Acta Psychiatrica Scandinavica</i> , 2021, 144, 521-523.	2.2	3
664	Adiposity in schizophrenia: A systematic review and meta-analysis. <i>Acta Psychiatrica Scandinavica</i> , 2021, 144, 524-536.	2.2	19
666	Antipsychotic Medications for Low-Income Preschoolers: Long Duration and Psychotropic Medication Polypharmacy. <i>Psychiatric Services</i> , 2022, 73, 510-517.	1.1	5
667	Physical activity and severe mental illness. , 0, , 385-408.		3
668	Monitoring of metabolic adverse events of second-generation antipsychotics in a naive paediatric population followed in mental health outpatient and inpatient clinical settings: MEMAS prospective study protocol. <i>BMJ Open</i> , 2021, 11, e040764.	0.8	0
669	Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT. <i>Health Technology Assessment</i> , 2021, 25, 1-124.	1.3	7
670	A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models. <i>PLoS ONE</i> , 2021, 16, e0246211.	1.1	6
672	Borderline Personality and Mood Disorders: Risk Factors, Precursors, and Early Signs in Childhood and Youth. , 2015, , 155-174.		2
673	Antipsychotics: Nonmotor Side Effects. <i>Current Clinical Psychiatry</i> , 2020, , 201-214.	0.2	2

#	ARTICLE	IF	CITATIONS
674	Psychopharmaka. , 2010, , 797-842.		4
676	Psychopharmaka. , 2012, , 833-879.		1
678	Pipamperone Population Pharmacokinetics Related to Effectiveness and Side Effects in Children and Adolescents. Clinical Pharmacokinetics, 2020, 59, 1393-1405.	1.6	10
679	Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 516-525.	0.7	42
680	The Human Rights of People with Severe and Persistent Mental Illness. , 2012, , 297-320.		8
681	The first draft of DSM-V. BMJ: British Medical Journal, 2010, 340, c1168-c1168.	2.4	36
682	Hyperprolactinemia with Antipsychotic Drugs in Children and Adolescents. International Journal of Pediatric Endocrinology (Springer), 2010, 2010, 159402.	1.6	15
683	Comparison of the effect of lithium plus quetiapine with lithium plus risperidone in children and adolescents with bipolar I disorder: a randomized clinical trial. Medical Journal of the Islamic Republic of Iran, 2017, 31, 90-95.	0.9	2
684	Behavioral Weight Loss Treatment for Youth Treated With Antipsychotic Medications. Scandinavian Journal of Child and Adolescent Psychiatry and Psychology, 2016, 4, 96-104.	0.3	11
685	Putative Mechanisms of Action and Clinical Use of Lithium in Children and Adolescents: A Critical Review. Current Neuropharmacology, 2019, 17, 318-341.	1.4	23
686	Association between Serum Lipids and Antipsychotic Response in Schizophrenia. Current Neuropharmacology, 2019, 17, 852-860.	1.4	26
687	Second Generation Antipsychotics in Aspergerâ€™s Disorder and High Functioning Autism: A Systematic Review of the Literature and Effectiveness of Meta-Analysis.. Current Clinical Pharmacology, 2013, 8, 370-379.	0.2	21
688	Pharmacologic treatment of schizophrenia. Dialogues in Clinical Neuroscience, 2010, 12, 345-357.	1.8	86
689	Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. Dialogues in Clinical Neuroscience, 2011, 13, 155-172.	1.8	38
690	Early Intervention in Psychosis: Effectiveness and Implementation of a Combined Exercise and Health Behavior Intervention Within Routine Care. Frontiers in Endocrinology, 2020, 11, 577691.	1.5	11
691	Atypical Antipsychotic Medications Disrupt the Cardio-Metabolic and Cardio-Immune Axes. , 2020, 12, .		2
692	Monitoring Psychiatric Medications in Children. Pediatric Annals, 2012, 41, 157-163.	0.3	1
693	Mental Health Issues in Foster Care. Pediatric Annals, 2016, 45, e342-e348.	0.3	15

#	ARTICLE	IF	CITATIONS
694	How to Interpret Findings Concerning Newly Approved Antipsychotic Agents. <i>Journal of Clinical Psychiatry</i> , 2012, 73, e27.	1.1	1
695	National Trends in Second-Generation Antipsychotic Augmentation for Nonpsychotic Depression. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 490-497.	1.1	34
696	Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 1519-1525.	1.1	30
697	Safety and Tolerability of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder in Pediatric Subjects (6-17 Years Old). <i>primary care companion for CNS disorders, The</i> , 2011, 13, .	0.2	27
698	Review of the Safety of Second-Generation Antipsychotics. <i>primary care companion for CNS disorders, The</i> , 2012, 14, .	0.2	16
699	Weight-Gain in Psychiatric Treatment: Risks, Implications, and Strategies for Prevention and Management. <i>Mens Sana Monographs</i> , 2010, 8, 53.	0.2	33
700	Adverse drug events in patients with mental disorder in an ambulatory setting. <i>International Journal of Applied & Basic Medical Research</i> , 2017, 7, 108.	0.2	5
701	Some side effects and effects on physical activity of second-generation antipsychotics: A study in children and adolescents. <i>Advanced Biomedical Research</i> , 2014, 3, 224.	0.2	1
702	Evaluation of Weight Gain and Metabolic Parameters among Adolescent Psychiatric Inpatients: Role of Health Promotion and Life Style Intervention Programs. <i>Journal of Metabolic Syndrome</i> , 2012, 01, .	0.1	9
703	Evaluation of Monitoring for Metabolic Effects in Children Treated With Second Generation Antipsychotics in a Pediatric Clinic. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2013, 18, 292-297.	0.3	11
704	Key Potentially Inappropriate Drugs in Pediatrics: The KIDs List. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2020, 25, 175-191.	0.3	36
705	Integrating precision medicine in the study and clinical treatment of a severely mentally ill person. <i>PeerJ</i> , 2013, 1, e177.	0.9	12
706	Metabolic monitoring in children 5 years of age and younger prescribed second-generation antipsychotic medications. <i>Mental Health Clinician</i> , 2017, 7, 1-6.	0.5	9
707	Evaluation of initial atypical antipsychotic monitoring parameters in children and adolescents. <i>Mental Health Clinician</i> , 2020, 10, 354-357.	0.5	1
708	Strategies for prevention and management of second generation antipsychotic-induced metabolic side effects. <i>Mental Health Clinician</i> , 2013, 3, 154-161.	0.5	6
709	Monitoring of Adverse Drug Reaction-Related Parameters in Children, Youth, and Young Adults Prescribed Antipsychotic Drugs by General Practitioners. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021, , .	0.7	1
711	Les psychotropes chez l'enfant. , 2010, , 244-260.		0
712	Pharmacotherapy for Pediatric Major Depression. <i>Psychiatric Annals</i> , 2010, 40, 192-202.	0.1	0

#	ARTICLE	IF	CITATIONS
713	Psychiatric Illness, Psychotropic Medication, and Childhood Obesity. , 2011, , 265-277.		0
715	Mercaderes en el Templo: hegemonía del paradigma bio-comercial en Psiquiatría. Revista De La Asociación Española De Neuropsiquiatría, 2011, 31, 321-341.	0.1	1
716	Monitoring and Treatment of Weight Gain in Children and Adolescents Treated with Second Generation Antipsychotics (SGAs). Mental Health Clinician, 2011, 1, 3-5.	0.5	0
717	Psychiatric Disorders - Worldwide Advances. , 2011, , .		1
718	Autistic Spectrum Disorders. , 2012, , 638-663.		1
720	Changes in weight and metabolic parameters following long-term iloperidone use: A meta-analysis of data from 9 Phase II and III trials of iloperidone. Open Journal of Psychiatry, 2012, 02, 414-422.	0.2	0
723	Pediatric Schizophrenia. , 2013, , 1-6.		0
725	Pharmacoepidemiological Study of Psychotropic Medication Use in Children with Developmental Disorders. IOSR Journal of Pharmacy, 2013, 3, 71-80.	0.1	0
726	Antipsychotics: A General View of Therapeutic and Adverse Effects. , 2013, , 23-65.		0
728	Psychotropes chez l'enfant. , 2014, , 361-380.		0
730	Nosology and Diagnostic Issues in Child and Adolescent Psychiatry. , 2015, , 255-274.		0
733	Pediatric Psychopharmacology: Perspectives from Low Resource Countries. , 2016, , 303-324.		0
737	Medical Comorbidities, Medications, and Sleep. , 2017, , 85-104.		0
739	Pediatric Medicine for the Child Psychiatrist. , 2018, , 23-44.		0
740	Psychosen. , 2018, , 133-164.		0
741	Psychopharmacology for play therapists.. International Journal of Play Therapy, 2018, 27, 35-45.	0.2	1
743	Olanzapine - Focus on the Cardiometabolic Side Effects. Serbian Journal of Experimental and Clinical Research, 2018, .	0.2	0
745	Antipsychotics and Cardiac Side Effects. , 2019, , 1-10.		0

#	ARTICLE	IF	CITATIONS
746	Schizophrenia: effects of aripiprazole in metabolic syndrome. Brazilian Journal of Pharmaceutical Sciences, 0, 55, .	1.2	2
747	Intervention Strategies for Attenuated Psychosis Syndromes: A Review of Current Practice, Evidence, and Future Directions. , 2019, , 41-63.		0
748	Behaviorally associated changes in neuroconnectivity following autologous umbilical cord blood infusion in young children with autism spectrum disorder. Annals of Translational Medicine, 2019, 7, S123-S123.	0.7	2
750	The Relative Risk of Developing Type 2 Diabetes Mellitus in Young Adults with Schizophrenia Treated with Different Atypical Antipsychotic. Romanian Journal of Diabetes Nutrition and Metabolic Diseases, 2019, 26, 445-453.	0.3	0
751	Antipsychotics and Cardiac Side Effects. , 2020, , 721-729.		0
753	The Development of a Nutrition Screening Tool for Mental Health Settings Prone to Obesity and Cardiometabolic Complications: Study Protocol for the NutriMental Screener. International Journal of Environmental Research and Public Health, 2021, 18, 11269.	1.2	7
754	Antipsychotic Use in the Prevention and Treatment of Intensive Care Unit Delirium in Pediatric Patients. Journal of Pediatric Pharmacology and Therapeutics, 2020, 25, 81-95.	0.3	12
755	First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2010, 19, 124-37.	0.7	51
756	Engaging families in research to determine health literacy needs related to the use of second-generation antipsychotics in children and adolescents. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2010, 19, 201-8.	0.7	5
757	Barriers and facilitators to implementation of a metabolic monitoring protocol in hospital and community settings for second-generation antipsychotic-treated youth. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2011, 20, 134-41.	0.7	15
758	Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2011, 20, 218-33.	0.7	65
759	Management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2011, 20, 234-41.	0.7	20
760	Management recommendations for metabolic complications associated with second-generation antipsychotic use in children and youth. Paediatrics and Child Health, 2011, 16, 575-80.	0.3	19
761	Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatrics and Child Health, 2011, 16, 581-9.	0.3	40
762	Review of the pharmacotherapy of irritability of autism. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2012, 21, 130-46.	0.7	25
765	Health Information Preference among Youth and Caregivers related to Second-Generation Antipsychotic Treatment. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2012, 21, 302-9.	0.7	3
766	Predictors of metabolic parameter monitoring in adolescents on antipsychotics in a primary care setting. Mental Health in Family Medicine, 2012, 9, 137-48.	0.2	6
768	Schizophrenia: overview and treatment options. P and T, 2014, 39, 638-45.	1.0	165

#	ARTICLE	IF	CITATIONS
769	Antidepressant use and body mass index change in overweight adolescents: a historical cohort study. <i>Innovations in Clinical Neuroscience</i> , 2014, 11, 14-21.	0.1	12
771	Pre and post-natal risk and determination of factors for child obesity. <i>Journal of Medicine and Life</i> , 2016, 9, 386-391.	0.4	35
772	Prescribing Practices of Quetiapine for Insomnia at a Tertiary Care Inpatient Child and Adolescent Psychiatry Unit: A Continuous Quality Improvement Project. <i>Journal of the Canadian Academy of Child and Adolescent Psychiatry</i> , 2017, 26, 98-103.	0.7	9
773	Second-generation antipsychotics in children: Risks and monitoring needs. <i>Canadian Family Physician</i> , 2018, 64, 660-662.	0.1	5
775	Long Term Metabolic and Inflammatory Effects of Second-Generation Antipsychotics: A Study in Mentally Disordered Offenders. <i>Journal of Personalized Medicine</i> , 2021, 11, 1189.	1.1	5
776	The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis. <i>Molecular Psychiatry</i> , 2022, 27, 1562-1572.	4.1	20
777	Aripiprazole in young people with early psychosis: a systematic review and meta-analysis of weight gain. <i>Australasian Psychiatry</i> , 2022, 30, 90-94.	0.4	2
778	Evaluation of carotid intima media thickness as an early marker of atherosclerosis in children and adolescents with autism spectrum disorder: a case-control study. <i>International Journal of Developmental Disabilities</i> , 2023, 69, 825-834.	1.3	2
779	Long-term safety and effectiveness of open-label lurasidone in antipsychotic-Naïve versus previously treated adolescents with Schizophrenia: A post-hoc analysis. <i>Schizophrenia Research</i> , 2022, 240, 205-213.	1.1	3
780	<scp>Meta-Analysis</scp> : Efficacy and Tolerability of Vesicular Monoamine Transporter Type 2 Inhibitors in the Treatment of Tic Disorders. <i>Movement Disorders</i> , 2022, , .	2.2	2
781	Previous exposure to antipsychotic drug treatment is an effective predictor of metabolic disturbances experienced with current antipsychotic drug treatments. <i>BMC Psychiatry</i> , 2022, 22, 210.	1.1	2
782	Autism Spectrum Disorder and Obesity in Children: A Systematic Review and Meta-Analysis. <i>Obesity Facts</i> , 2022, 15, 305-320.	1.6	20
783	Effects of Regular Physical Exercises on Physical and Mental Development and Quality of Life in Autism Spectrum Disorders. <i>Çocuk Ve Genişlik Ruh Sağılığı Dergisi / Turkish Journal of Child and Adolescent Mental Health</i> , 2022, 29, 1-6.	0.2	1
784	Elevated atherogenic lipid profile in youth with bipolar disorder during euthymia and hypomanic/mixed but not depressive states. <i>Journal of Psychosomatic Research</i> , 2022, 156, 110763.	1.2	1
785	The Effect of Atypical Anti-psychotic Agents on Obesity and Glucose Metabolism. <i>Journal of Medicine and Life Science</i> , 2021, 18, 49-55.	0.1	0
786	Probiotics Plus Dietary Fiber Supplements Attenuate Olanzapine-Induced Weight Gain in Drug-Naïve First-Episode Schizophrenia Patients: Two Randomized Clinical Trials. <i>Schizophrenia Bulletin</i> , 2022, 48, 850-859.	2.3	16
787	Effectiveness of a Fitbit Based Sleep and Physical Activity Intervention in an Early Intervention Psychosis (EIP) Service. <i>Open Journal of Psychiatry</i> , 2022, 12, 188-202.	0.2	2
788	How to Mitigate Risk of Premature Cardiovascular Disease Among Children and Adolescents with Mental Health Conditions. <i>Current Atherosclerosis Reports</i> , 2022, 24, 253-264.	2.0	4

#	ARTICLE	IF	CITATIONS
789	Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia. <i>European Psychiatry</i> , 2022, 65, 1-35.	0.1	4
790	Study of the acute and repeated dose 28-day oral toxicity in mice treated with PT-31, a molecule with a potential antipsychotic profile. <i>Toxicology Mechanisms and Methods</i> , 2022, 32, 705-715.	1.3	1
800	Interaction between Weight and Medications in Psychological Illnesses of Children. <i>World Review of Nutrition and Dietetics</i> , 2013, 106, 174-180.	0.1	0
801	Core Signs and Symptoms in Children with Autism Spectrum Disorder Improved after Starting Risperidone and Aripiprazole in Combination with Standard Supportive Therapies: A Large, Single-Center, Retrospective Case Series. <i>Brain Sciences</i> , 2022, 12, 618.	1.1	3
802	Long-term metabolic and inflammatory effects of second-generation antipsychotics: A study in mentally disordered offenders. , 2022, 2, .		0
803	Practitioners' Perspective on Metabolic Monitoring of Second-Generation Antipsychotics: Existing Gaps in Knowledge, Barriers to Monitoring, and Strategies. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2022, 32, 296-303.	0.7	1
804	Medicaid Expenditures among Children with Documented Obesity. <i>Childhood Obesity</i> , 0, , .	0.8	0
805	Long-term treatment of antipsychotics and combined therapy with other psychotropic medications inducing weight gain in patients with non-affective psychotic disorder: Evidence from GROUP, a longitudinal study. <i>Psychiatry Research</i> , 2022, 314, 114680.	1.7	3
806	Treatment of preschool children with obsessive compulsive disorder. <i>Clinical Child Psychology and Psychiatry</i> , 0, , 135910452211118.	0.8	0
807	Differences in body mass index trajectories of adolescent psychiatric inpatients by sex, age, diagnosis and medication: an exploratory longitudinal, mixed effects analysis. <i>Child and Adolescent Mental Health</i> , 0, , .	1.8	0
808	The metabolic adverse effects of antipsychotic use in individuals with intellectual and/or developmental disability: A systematic review and meta-analysis. <i>Acta Psychiatrica Scandinavica</i> , 2022, 146, 201-214.	2.2	5
809	Oxidative stress parameters and antioxidants in adults with unipolar or bipolar depression versus healthy controls: Systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2022, 314, 211-221.	2.0	18
810	Nutrition interventions for youth with dyslipidemia: a National Lipid Association clinical perspective. <i>Journal of Clinical Lipidology</i> , 2022, 16, 776-796.	0.6	5
811	Alterations in sorting and secretion of hepatic apoA5 induce hypertriglyceridemia due to short-term use of olanzapine. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
812	Use of an Interactive Obesity Treatment Approach in Individuals With Severe Mental Illness: Feasibility, Acceptability, and Proposed Engagement Criteria. <i>JMIR Formative Research</i> , 2022, 6, e38496.	0.7	5
813	Pharmacological interventions for prevention of weight gain in people with schizophrenia. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	7
814	Psychosen im Kindes- und Jugendalter. <i>Springer Reference Medizin</i> , 2021, , 1-37.	0.0	0
815	ROLE OF FOLINIC ACID IN IMPROVING THE ADAPTIVE SKILLS AND LANGUAGE IMPAIRMENT IN CHILDREN WITH AUTISM SPECTRUM DISORDER. <i>Khyber Medical University Journal</i> , 2021, 14, 197-200.	0.1	0

#	ARTICLE	IF	CITATIONS
816	Complementary and Integrative Health Medicine in Tourette Syndrome. , 2022, , 496-508.		0
818	The Role of the Microbiome in the Metabolic Health of People with Schizophrenia and Related Psychoses: Cross-Sectional and Pre-Post Lifestyle Intervention Analyses. <i>Pathogens</i> , 2022, 11, 1279.	1.2	1
819	Responding to the Challenge of Multimorbidity in People with Serious Mental Illness. <i>Annals of the Academy of Medicine, Singapore</i> , 2013, 42, 489-491.	0.2	2
820	How do people with first episode psychosis experience therapeutic relationships with mental health practitioners? A narrative review. <i>Psychosis</i> , 0, , 1-12.	0.4	0
821	Weight changes in people with early psychosis treated with oral or long-acting injectable aripiprazole. <i>Schizophrenia Research</i> , 2023, 251, 74-81.	1.1	0
822	Trends in antipsychotic prescribing in children and adolescents: more is not necessarily better. <i>Lancet Psychiatry</i> , 2023, 10, 75-76.	3.7	0
823	Early Family Intervention for Youth at Risk for Bipolar Disorder: Psychosocial and Neural Mediators of Outcome. <i>Current Neuropharmacology</i> , 2023, 21, 1379-1392.	1.4	1
824	Multilevel Pharmacological Effects of Antipsychotics in Potential Glioblastoma Treatment. <i>Current Topics in Medicinal Chemistry</i> , 2023, 23, .	1.0	0
825	Fourteen-year trends in the prescribing patterns of pediatric bipolar patients discharged from two public mental hospitals in Taiwan. <i>Asia-Pacific Psychiatry</i> , 0, , .	1.2	1
826	Glucose and Lipid Profiles Predict Anthropometric Changes in Drug-Naïve Adolescents Starting Treatment with Risperidone or Sertraline: A Pilot Study. <i>Biomedicines</i> , 2023, 11, 48.	1.4	3
827	Association Between Autism Spectrum Disorders and Cardiometabolic Diseases. <i>JAMA Pediatrics</i> , 2023, 177, 248.	3.3	12
828	Psychiatric Disorders and Obesity in Childhood and Adolescence—A Systematic Review of Cross-Sectional Studies. <i>Children</i> , 2023, 10, 285.	0.6	10
829	Double-blind, randomised placebo-controlled clinical trial of metformin as an adjunct to a sleep-wake, activity and metabolically focused behavioural intervention to improve cardiometabolic outcomes and mood symptoms in youth with major mood syndromes: study protocol. <i>BMJ Open</i> , 2023, 13, e064682.	0.8	1
830	Efficacy of stimulants for preschool attention-deficit/hyperactivity disorder: A systematic review and meta-analysis. <i>JCPP Advances</i> , 2023, 3, .	1.4	3
831	Metformin for Overweight and Obese Children With Bipolar Spectrum Disorders Treated With Second-Generation Antipsychotics (MOBILITY): Protocol and Methodological Considerations for a Large Pragmatic Randomized Clinical Trial. , 2023, 1, 60-73.		2
832	Efficacy and Safety of Second-generation Antipsychotics in Schizophrenia Pharmacotherapy: A Comparative Narrative Review. , 2022, 18, 183-190.		0
833	Antipsychotic-Related Prolactin Levels and Sexual Dysfunction in Mentally Ill Youth: A 3-Month Cohort Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2023, 62, 1021-1050.	0.3	5
834	Cardiometabolic Monitoring and Sociodemographic and Clinical Characteristics of Youths Prescribed Antipsychotic Medications. <i>Psychiatric Services</i> , 2023, 74, 801-808.	1.1	4

#	ARTICLE	IF	CITATIONS
835	Experience and Impact of the "Well-Track" Physical Activity and Sleep Tracker Based Healthy Lifestyle Intervention for Patients in an Early Intervention in Psychosis (EIP) Service. Open Journal of Psychiatry, 2023, 13, 73-93.	0.2	1
841	Treatment-resistant depression in children and adolescents. Progress in Brain Research, 2023, , .	0.9	0
853	Disruptive Affektregulationsstörungen in Kindheit und Jugend. Springer Reference Medizin, 2022, , 1-13.	0.0	0
856	Manische Episode und bipolare affektive Störung. , 2023, , 615-628.		0
864	Ernährungsaspekte bei psychischen Störungen. , 2023, , 229-238.		0